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isomers are also available on the drug market is currently not 
known. 
4,4′-DMAR has been advertised under the name ‘Serotoni’ and 
is available for purchase from online retailers as a ‘research 
chemical’ in either powder or tablet/pellet form. It appears 
that the number of Internet shops advertising this particular 
substance may be declining. Information from the Member 
States suggests that 4,4′-DMAR is sold as a drug in its own 
right, and surreptitiously as ecstasy and other illicit drugs. 
Seized tablets found to contain 4,4′-DMAR showed a range of 
shapes, markings and logos (2), thus raising the likelihood that 
these particular products were designed to be sold as 
‘ecstasy’ tablets on the illicit drug market. 
One analytically confirmed non-fatal intoxication has been 
reported by Poland and 31 deaths associated with 4,4′-DMAR 
have been reported by Hungary (eight deaths), Poland (one 
death) and the United Kingdom (22 deaths). The deaths in 
Hungary occurred between June and October 2013, the 
Polish death occurred in July 2013 and those in the United 
Kingdom occurred between June 2013 and June 2014. Data 
on gender and age are currently available for 30 of the 
decedents. Twenty-two were male (four from Hungary; one 
from Poland; 17 from the United Kingdom); eight were female 
(four from Hungary; four from the United Kingdom); they were 
aged between 16 and 43 years. 4,4′-DMAR was detected in 
post-mortem biological samples in all of the 31 deaths. With 
the exception of one case, the presence of one or more 
psychoactive substances (and/or their metabolites) in 
post-mortem biological samples was noted. 
There are no coordinated national or European population 
surveys on the prevalence of 4,4′-DMAR use. There is no 
information to suggest that 4,4′-DMAR has any industrial, 
cosmetic or medicinal use. 
(2)  It is common to find markings on tablets sold as ‘ecstasy’, including those of 
popular cultural and iconic brands often having an association with quality. 
I Summary
The substance 4-methyl-5-(4-methylphenyl)-4,5-
dihydrooxazol-2-amine (4,4′-dimethylaminorex, 4,4′-DMAR) is 
a synthetic, substituted oxazoline derivative. 4,4′-DMAR is also 
a derivative of 4-methylaminorex (4-MAR) and aminorex, both 
of which are stimulants and controlled under the 1971 United 
Nations Convention on Psychotropic Substances. Limited 
information suggests that 4,4′-DMAR has stimulant-type 
effects. 
The detection of 4,4′-DMAR on the European drug market was 
first officially notified to the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) through the EU Early 
Warning System by the Netherlands national focal point on 
10 December 2012 and related to a seizure made by customs 
authorities of 500 g of white powder that had arrived from 
India in the previous month. Nine Member States (Denmark, 
Finland, France, Hungary, the Netherlands, Poland, Romania, 
Sweden and the United Kingdom) reported detections (1) of 
4,4′-DMAR. This substance has typically been seized as 
powders or tablets. In most cases, 4,4′-DMAR was reported as 
the only active constituent, while in about 20 % of detections 
it was found in combination with other substances. Most of 
the Member States reported a small number of seizures; 
however, in the case of the Netherlands these totalled more 
than 90 kg of powder. 
Chemically, 4,4′-DMAR can exist in the form of two different 
racemic (±)-cis and (±)-trans mixtures or four distinct 
enantiomers. In cases where sufficient analytical data were 
available from collected and biological sample analyses, the 
presence of the cis form was indicated. Whether the trans 
(1)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, 
etc.) and/or specimens (tissues, hair, etc.).
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Compared to other types of new psychoactive substances 
(such as the synthetic cathinones) there are limited self-
reported experiences with 4,4′-DMAR on user websites. 
4,4′-DMAR appears to be generally recognised by users as a 
stimulant, and is used in a range of ‘doses’. Single dosage 
levels may range between 10 mg and 200 mg, depending on 
the route of administration. Oral administration and nasal 
insufflation are commonly reported; inhalation of the drug has 
also been mentioned. In one of the deaths reported to the EU 
Early Warning System the drug had been injected (the specific 
route of injection was not reported). Warning messages have 
been posted on user websites by users about comparatively 
long-lasting effects and the potential for adverse reactions 
(such as perceived serotonin toxicity), especially when taken 
in combination with other substances including alcohol.
The first formal scientific investigations into the chemical, 
analytical and pharmacological properties of cis- and trans-
4,4′-DMAR appeared in 2014. Monoamine transporter activity 
studies in rat brain synaptosomes using d-amphetamine, 
aminorex and 4-methylaminorex as control compounds, 
showed that cis-4,4′-DMAR was a potent, non-selective and 
fully efficacious substrate-type releaser at transporters for 
dopamine (DAT), norepinephrine (NET), and serotonin (SERT). 
The potency of cis-4,4′-DMAR at DAT and NET rivalled that of 
other psychomotor stimulant drugs like d-amphetamine and 
aminorex. However, cis-4,4′-DMAR had much more potent 
actions at SERT. The trans-4,4′-DMAR isomer was also found 
to be a potent releasing agent at DAT and NET while acting as 
an uptake blocker at SERT, thus showing a ’hybrid’ profile. 
Both cis- and trans-4,4′-DMAR isomers were also more potent 
than (S)-(+)-3,4-methylenedioxymethamphetamine ((S)-(+)-
MDMA) as catecholamine releasers.
I  Section A. Physical, chemical, pharmaceutical and pharmacological information
I  A1. Physical, chemical and pharmaceutical information
A1.1. Physical and chemical description
Chemical description and names
4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine 
(4,4′-DMAR) is a synthetic substituted oxazoline derivative. It 
can also be classified as an analogue of 4-methylaminorex 
(4-MAR) and aminorex, both of which are psychostimulants 
and controlled under the 1971 United Nations Convention on 
Psychotropic Substances (3). The structures of 4,4′-DMAR, 
4-MAR and aminorex are provided in Figure 1.
(3)  4-MAR is listed in Schedule I and aminorex is listed in Schedule IV of the 1971 
United Nations Convention on Psychotropic Substances.
FIGURE 1
The molecular structure, formula, relative molecular weight and monoisotopic mass of 4,4′-DMAR
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Molecular formula: C11H14N2O
Molecular weight: 190.25
Monoisotopic mass: 190.1106
Molecular formula: C10H12N2O
Molecular weight: 176.22
Monoisotopic mass: 176.0950
Molecular formula: C9H10N2O
Molecular weight: 162.19
Monoisotopic mass: 162.0793
Note: Structures of 4-MAR and aminorex are provided for comparison. Asterisk indicates chiral carbon.
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TABLE 1
Alternative names, codenames, street names, and 
abbreviations that may be encountered for 4,4′-DMAR
4-Methyl-5-(p-tolyl)-4,5-dihydrooxazol-2-amine
4,5-Dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine
[4-Methyl-5-(p-tolyl)-2-oxazolin-2-yl]amine
4-Methyl-5-(para-methylphenyl)-2-amino-oxazoline
para-Methyl-4-methylaminorex
p-Methyl-4-methylaminorex
4-Methylaminorex p-methyl derivative
4,4′-Dimethylaminorex
p4-DMAR
4-methyl-euphoria
4-methyl-U4Euh
4-M-4-MAR
Serotoni
ST
ST60
The systematic (International Union of Pure and Applied 
Chemistry, IUPAC) name is 4-methyl-5-(4-methylphenyl)-4,5-
dihydro-1,3-oxazol-2-amine. Other commonly encountered 
names, codenames, street names, and abbreviations are given 
in Table 1. Chemical Abstract Service (CAS) registry numbers 
are given in Table 2.
TABLE 2
Chemical Abstract Service (CAS) Registry Numbers for 
4,4′-DMAR
CAS Registry Numbers Variant
1445569-01-6 Form not specified
364064-08-4 (4S,5S) Free base
The words ‘euphoria’ and ‘U4Euh’, used in some of the street 
names of 4,4′-DMAR (Table 1), are references to two of the 
street names given to 4-methylaminorex (4-MAR) (4), a 
psychostimulant encountered in the 1980s (By et al., 1989; 
Cooper, 1988; Davis and Brewster, 1988; Klein et al., 1989). 
Aminorex (5), i.e. the analogue without both methyl groups at 
the para- and 4-position contained in 4,4′-DMAR, was briefly 
available as an appetite suppressant in Europe during the late 
1960s but was withdrawn from the market due to an 
association with primary pulmonary hypertension (Gurtner, 
1979, 1985).
The presence of two chiral centres within the oxazoline ring of 
4,4′-DMAR gives rise to four enantiomers or two (±)-cis and 
(±)-trans racemates, as shown in Figure 2 (6). However, it 
seems unlikely that any of the enantiopure forms would 
appear on the drug market, due to additional complexities 
involved in their preparation.
(4)  Other street names for 4-methylaminorex include: 4-MAX, McN-822 and ‘ICE’ 
(before this term was more frequently used for methamphetamine).
(5)  5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine (aminoxafen; aminoxaphen; apiquel; 
CPDD-0039; McN-742; NSC-66592; NSC-66952).
(6)  (±) is used to denote the presence of the racemic mixture. For reasons of 
clarity it will be omitted in the remaining text when reference is made to either 
cis- or trans 4,4′-DMAR instead of (±)-cis- and (±)-trans-4,4′-DMAR, 
respectively.
FIGURE 2
Molecular structures of the four possible 4,4′-DMAR enantiomers
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Identification and analytical profile
An extensive analytical characterisation and preparation of 
both cis- and trans-4,4′-DMAR racemates has recently been 
reported (Brandt et al., 2014). These included 1H and 13C 
nuclear magnetic resonance spectroscopy (NMR), electron- 
and chemical ionisation (EI/CI), electrospray (ESI) triple 
quadrupole and high-resolution mass spectrometry, Fourier 
transform infrared spectroscopy (FTIR), ultraviolet-visible 
spectroscopy, gas (GC)- and liquid chromatography (LC) and 
X-ray crystallography. The differentiation of cis and trans 
racemates may be facilitated by implementation of FTIR, NMR 
or adequate separation techniques. Chiral resolution of all four 
enantiomers may be obtained from derivatisation and 
synthesis or separation using appropriate preparatory 
stationary phases. 
Analysis by EI-MS revealed the presence of key fragments at 
m/z 190 (M??), 175, 146, 119, 91, 70 (base peak) and m/z 43, 
respectively. The EI spectra of both racemates are identical as 
expected. Collision-induced dissociation of the protonated 
molecule [M+H]+ at m/z 191 under ESI-MS/MS conditions 
gave key product ions at m/z 148 (base peak, depending on 
collision energy), 131, 116, 105, 91 and 56. Challenges (e.g. 
peak broadening or artificially induced isomerisation) may be 
encountered during characterisation by GC-MS. 
Differentiation between cis- and trans-4,4′-DMAR may also be 
obtained by NMR analysis:
cis-4,4′-DMAR free base: 1H NMR (CDCl3) δ 7.20 (d, J = 7.8 Hz, 
2 H, Ar H), 7.12 (d, J = 7.8 Hz, 2 H, Ar H), 5.74 (d, J = 8.7 Hz, 
H-5), 4.41 (dq, J = 8.7, 6.8 Hz, H-4), 2.38 (s, 3 H, Ar-CH3) and 
0.84 (d, J = 6.8 Hz, 3 H, CH3); 
13C NMR (CDCl3) δ 160.90 (C-2), 
138.30 (Ar-C), 131.71 (Ar-C), 129.04 (Ar-CH), 125.85 (Ar-CH), 
85.59 (C-5), 59.50 (C-4), 21.07 (Ar-CH3) and 17.59 (CH3).
trans-4,4′-DMAR free base: 1H NMR (CDCl3) δ 7.23 (m, 4 H, Ar 
H), 5.08 (d, J = 7.7 Hz, 1 H, H-5), 4.05 (dq, J = 7.7, 6.2 Hz, 1 H, 
H-4), 2.38 (s, 3 H, Ar-CH3) and 1.40 (d, J = 6.2 Hz, 3 H, CH3); 
13C NMR (CDCl3) δ 160.49 (C-2), 139.34 (Ar-C), 133.84 (Ar-C), 
129.76 (Ar-CH), 126.31 (Ar-CH), 90.25 (C-5), 63.71 (C-4), 
21.03 (Ar-CH3) and 20.08 (CH3). 
The direct analysis of 4,4′-DMAR (e.g. as a powder, tablet or in 
liquid form) can be carried out using standard techniques. 
Detection in biological fluids may require the implementation 
of more sensitive technology including single or tandem mass-
spectrometry, in cases where low concentrations may be 
encountered in the sample matrices. Detection methods such 
as GC-MS, HPLC and/or LC-MS have been applied and 
published as part of a recent case series relating to 18 deaths 
associated with 4,4′-DMAR in the United Kingdom (Cosbey et 
al., 2014) (7) (Section D1.2.3). Data from these deaths and 
others reported by the United Kingdom, and data from a 
collected sample purchased from an Internet retailer (8), 
indicate that it is the cis form of 4,4′-DMAR on the drug market 
(Brandt et al., 2014). Information about the presence and 
prevalence of its trans counterpart is unavailable but the 
potential for its appearance cannot be excluded. The 
implementation of analytical procedures applied to low 
concentration sample matrices able to differentiate between 
the cis and the trans forms requires access to suitable 
reference material. It is worth noting that the preparation and 
analytical characterisation of the 3,4-dimethylaminorex 
isomers (both methyl groups present on the oxazoline ring) 
has been described in the literature (Noggle et al., 1992) and 
analytical differentiation from 4,4′-DMAR would not be 
expected to cause difficulties (9). One of the trans enantiomers 
appears to have been discussed on an online forum and called 
‘4-DMAR’ and ‘Direx’ (10).
There is no information on presumptive colour tests with 
4,4′-DMAR. 
As of August 2014 there is no immunoassay field test for 
4,4′-DMAR. Data on cross-reactivity with commercially 
available urine immunoassay tests used for standard drugs 
of abuse are currently unavailable. Information related to a 
death reported by Poland (Section D1.2.3) noted that 
preliminary screening with an ELISA test pointed towards the 
presence of amphetamine, methamphetamine and 
benzodiazepines. Blood analysis carried out by LC-MS/MS, 
however, confirmed the presence of 4,4’-DMAR, 
N-ethylbuphedrone (NEB), midazolam and α-hydroxy-
midazolam instead. 
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS Registry Numbers listed above and no information was 
found.
Physical description 
The free base of both cis and trans forms have been described 
as colourless solids with melting points of 136–138°C 
(cis-4,4′-DMAR) and 101–103°C (trans-4,4′-DMAR). The 
melting point of a recrystallised cis-4,4′-DMAR hydrochloride 
(7)  These 18 deaths are included in those that have been reported by the United 
Kingdom. 
(8)  The term ‘Internet retailer’ is used in this report to describe Internet shops that 
offer new psychoactive substances for sale, often advertising them as ‘legal 
highs’ and ‘research chemicals’. 
(9)  Another isomer 3’,4-DMAR (‘Serotoni 2.0’), i.e. carrying the methyl group in 
the meta- instead of the para-position, has been mentioned on the Internet 
(serotoni.info, 2014), although data on this compound seem to be unavailable 
at present. 
(10) www.drugs-forum.com/forum/showthread.php?t=83865 (August 2014).
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salt sample obtained from an Internet retailer was given as 
163–165°C (ethyl acetate/methanol) (Brandt et al., 2014) 
(Section C). The cis-4,4′-DMAR HCl salt is a white crystalline 
powder and soluble in water. Commercially available analytical 
reference standards for all enantiomers and both racemic 
forms are expected to be available in the near future. Section 
A1.2 provides a description of the physical forms reported by 
Member States.
Methods and chemical precursors used for the 
manufacture of 4,4′-DMAR
Information is not available regarding manufacturing sites, 
precursors or synthetic methods used for 4,4′-DMAR 
detected on the drug market in Europe. A report on the 
syntheses of cis- and trans-4,4′-DMAR was first published in 
2014 and is outlined in Figure 3 (Brandt et al., 2014). 
Important key intermediates in this reaction are the 
cathinone (normephedrone) intermediate and the reduced 
alcohol. Conversion to cis- and trans-4,4′-DMAR was 
achieved with either cyanogen bromide (BrCN) or potassium 
cyanate (KOCN), respectively, based on a number of 
variations published in the earlier literature related to the 
chemistry of aminorex-type compounds (e.g. Fodor and 
Koczka, 1952; Poos et al., 1963; Rodriguez and Allred, 2005). 
Interestingly, the idea of synthesising 4,4′-DMAR following 
established aminorex-type chemistry was discussed on an 
online forum at least as early as 2003, although it is unclear 
whether this was ever taken further to the preparatory 
stage (11).
Typical impurities encountered in seized and collected 
samples
Detailed information is not available with regard to route-
specific by-products produced during the synthesis of 
4,4′-DMAR. In addition, there are no quantitative data currently 
available on the impurities detected in seized and collected 
samples. Analyses of seized powder and tablet materials 
(Section C) have revealed mixtures with other new 
psychoactive substances such as pentedrone (12), 
methcathinone, MPPP (13), alpha-PVP (14), bk-MPA (15), 
(11) For example, some of the files for ‘The Hive’ forum (defunct since 2004) have 
been archived (‘Hive filez’). The contemplation on a potential 4,4′-DMAR synthesis 
was posted on 05.04.2003 (post no. 424141). The Hive was an online discussion 
forum for individuals interested in the practical synthesis of psychoactive 
substances, their use, and the related social and policy issues.
(12) 2-(Methylamino)-1-phenylpentan-1-one
(13) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one
(14) 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one
(15) 2-(Methylamino)-1-(thiophen-2-yl)propan-1-one
FIGURE 3
Synthesis of cis- and trans-4,4′-DMAR, as reported by Brandt et al., 2014
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PVP (16), mephedrone (17), UR-144 (18), RH-34 (19), 
ethylphenidate and 5-APDB (20). In one case from Hungary, 
the presence of creatine monohydrate was reported to be 
present as a cutting agent. In the majority of cases 4,4′-DMAR 
was the main constituent.
A1.2. Physical/pharmaceutical form
Reports of seizures and collected samples have noted that 
4,4′-DMAR has typically been obtained in the form of powders 
and tablets (EMCDDA and Europol, 2014). The majority of 
powders are white, but other samples have also been 
described as pale yellow, pink, green and blue coloured 
powders. Tablets have been observed in various colours and 
shapes, some of which bore logos such as ‘Playboy’, ‘Heart’, 
‘Mitsubishi’, ‘Star’, ‘Transformers’, ‘Cherries’ and ‘Cross’. The 
analysis of a collected sample of 5 g of 4,4′-DMAR in the form 
of a white powder sample obtained from an Internet retailer 
confirmed the presence of the cis form as a hydrochloride salt 
(Brandt et al., 2014). Section C provides further details of the 
seized and the collected sample of 4,4′-DMAR.
A1.3. Route of administration and dosage
Information provided by the Member States and from user 
websites (21) suggests that common routes of administration 
for 4,4′-DMAR are nasal insufflation and oral 
administration (22). In the latter case, consumption of tablets 
and ‘bombing’, i.e. the practice of wrapping powder in 
cigarette paper (or similar) prior to swallowing, have been 
noted. One self-reported experience from a user website 
notes the inhalation of 20 mg 4,4′-DMAR, which appeared to 
be based on the application of heat to what was described as 
a ‘methpipe’. In this instance this was preceded by oral 
administration of 40 mg (23). In one of the deaths reported by 
Hungary to the EU Early Warning System the drug had been 
injected (specific route of injection not reported). The physical 
forms detected in seizures and the collected sample would 
appear to be consistent with these routes of administration 
(Section C). 
Limited information on user websites suggests that a range of 
‘doses’ are used. ‘Low doses’ were reported as 10–15 mg 
insufflated or 10–25 mg oral, with a ‘high oral dose’ being 
(16) Presumed to refer to alpha-PVP, i.e. 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one
(17) 2-(Methylamino)-1-(4-methylphenyl)propan-1-one
(18) (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
(19) 3-{2-[(2-Methoxybenzyl)amino]ethyl}quinazoline-2,4(1H,3H)-dione
(20) 1-(2,3-Dihydro-1-benzofuran-5-yl)propan-2-amine
(21) The term ‘user website’ is used to describe Internet drug discussion forums 
and related websites.
(22) www.chemsrus.com (2014); www.drugs-forum.com (2014); serotoni.info 
(2014); www.bluelight.org (2014); www.ukchemicalresearch.org (2014).
(23) www.zoklet.net/bbs/showthread.php?t=289735 (15 August 2014).
reported as 120 mg (24). Another site reported the ‘dosage’ 
(not further described) as 30–100 mg (25). Oral ‘doses’ of 
between 60 and 200 mg and 65 mg insufflation have also 
been mentioned, in addition to dosage levels of ‘around 
360 mg over the course of around 4–5 hrs’ (26).
Information from Member States, particularly in relation to the 
deaths associated with 4,4′DMAR, and from user websites (27) 
suggests that 4,4′-DMAR may be used on its own or in 
combination with other psychoactive substances.
I  A2. Pharmacology, including pharmacodynamics and pharmacokinetics 
Pharmacodynamics
While a number of nonclinical studies have been published 
on the psychostimulant-like properties of 4-methylminorex 
(e.g. Ashby et al., 1995; Batsche et al., 1994; Bunker et al., 
1990; Glennon and Misenheimer, 1990; Goodman, 1990; 
Hanson et al., 1992; Hanson et al., 1999; Kankaanpää et al., 
2002; Mansbach et al., 1990; Meririnne et al., 2005; 
Roszkowski and Kelley, 1963; Russell et al., 1995; Yelnosky 
and Katz, 1963; Young and Glennon, 1993, 1998), data on 
4,4′-DMAR are more limited due to its recent emergence on 
the drug market.
Recent in vitro investigations on the monoamine transporter 
activity of cis-4,4′-DMAR using rat brain synaptosomes 
(Baumann et al., 2012, Rothman et al., 2003) revealed a 
robust ability to induce release of dopamine, noradrenaline 
and serotonin at the dopamine transporter (DAT), 
noradrenaline transporter (NET) and serotonin transporter 
(SERT), respectively (Brandt et al., 2014). d-Amphetamine, 
aminorex and cis-4-MAR (4-methylaminorex) were used as 
control compounds. The determination of dose-response 
curves (Figure 4) and potency values (expressed as half 
maximal effective concentrations, EC50, Table 3) revealed 
potent releasing activity of all compounds at DAT. 
Considerable potency values were also obtained for NET while 
activity at SERT varied more than 100-fold across the four 
substances, with (±)-cis-4,4′-DMAR exhibiting the highest 
potency at releasing serotonin (EC50 = 18.5 ± 2.8 nM). These 
results suggested that cis-4,4′-DMAR is a potent efficacious 
releaser at DAT, NET and SERT in rat brain tissue with 
comparable potency at DAT and NET to that of 
(24) www.drugs-forum.com/forum/showthread.php?t=216908 (April 2014).
(25) serotoni.info (April 2014).
(26) www.ukchemicalresearch.org/Thread-Serotoni-Powder-Serotonin-
Syndrome-and-Stimulant-Psychosis (April 2014) and www.chemsrus.com/
forum/6-stimulants/7358-serotoni?limit=10&start=40 (April 2014).
(27) www.drugs-forum.com/forum/showthread.php?t=216908 (April 2014).
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d-amphetamine and aminorex. Table 3 also shows that the 
potency of cis-4,4′-DMAR to release catecholamines was 
lower than that observed for cis-4-MAR. On the other hand, 
cis-4,4′-DMAR exerted much more potent actions at SERT 
when compared to d-amphetamine, aminorex and cis-4-MAR 
(Brandt et al., 2014).
FIGURE 4
Dose-response effects of d-amphetamine, aminorex, cis-4-MAR and cis-4,4′-DMAR in evoking release from DAT, NET and 
SERT in rat brain synaptosomes (Brandt et al., 2014)
TABLE 3
Stimulation of release in rat brain synaptosomes (a)
Drug Release at DATEC50 (nM) 
Release at NET
EC50 (nM) 
Release at SERT
EC50 (nM) 
DAT/SERT ratio (b)
d-Amphetamine 5.5 ± 0.5 8.2 ± 1.6 2602 ± 494 473
Aminorex 9.1 ± 0.9 15.1 ± 3.5 414 ± 78 45
cis-4-MAR (c) 1.7 ± 0.2 4.8 ± 0.9 53.2 ± 6.8 31
cis-4,4′-DMAR 8.6 ± 1.1 26.9 ± 5.9 18.5 ± 2.8 2
(a)  Table modified from Brandt et al., 2014. DAT: dopamine transporter; NET: norepinephrine transporter; SERT: serotonin transporter; [3H]-1-methyl-4-phenylpyridinium 
([3H]MPP+) used as radiolabeled substrate for DAT and NET and [3H]5-HT (serotonin) for SERT. Data expressed as mean ± SD for N = 3–4 experiments performed 
in triplicate.
(b)  DAT/SERT ratio calculated by (EC50 at DAT)
-1/ (EC50 at SERT)
-1; higher value = greater DAT selectivity.
(c) cis-4-Methylaminorex racemate.
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A comparison between cis- and trans-4,4′-DMAR under 
identical assay conditions, i.e. monoamine transporter release 
using rat brain synaptosomes, showed that trans-4,4′-DMAR 
was also a fully efficacious releasing agent at DAT and NET, 
although slightly less potent than the cis isomer (Figure 5, 
Table 4). The key difference between the cis and trans isomers 
was observed at SERT where the trans isomer acted as an 
uptake blocker, which indicated that trans-4,4′-DMAR 
displayed a ‘hybrid’ profile of a catecholamine releaser with 
5-HT uptake blocking properties (McLaughlin et al., 2014). The 
extent to which some pharmacological overlaps between 
4,4-DMAR and MDMA might translate to 
psychopharmacological overlap in humans has not been 
investigated.
FIGURE 5
Dose-response effects of cis- and trans-4,4′-DMAR compared to (S)-(+)-3,4-methylenedioxymethamphetamine 
((S)-(+)-MDMA)) in evoking release from DAT, NET and SERT in rat brain synaptosomes (McLaughlin et al., 2014)
TABLE 4
Stimulation of release in rat brain synaptosomes (a)
Drug Release at  DAT EC50 (nM) 
Release at  
NET EC50 (nM)
Release at  
SERT EC50 (nM)
DAT/SERT ratio (c)
(S)-(+)-MDMA (b) 143 ± 16 98.3 ± 15.0 85.0 ± 13.3 0.6
cis-4,4′-DMAR 10.9 ± 0.7 11.8 ± 2.0 17.7 ± 2.3 1.6
trans-4,4′-DMAR 24.4 ± 2.7 31.6 ± 4.6 59.9 ± 17.2 (d) 2.5
(a)  Table modified from McLaughlin et al. (2014). DAT: dopamine transporter; NET: norepinephrine transporter; SERT: serotonin transporter; [3H]-1-methyl-4-
phenylpyridinium ([3H]MPP+) used as radiolabeled substrate for DAT and NET and [3H]5-HT (serotonin) for SERT. Data expressed as mean ± SD for N = 3-4 
experiments performed in triplicate.
(b) (S)-(+)-3,4-Methylenedioxymethamphetamine.
(c) DAT/SERT ratio calculated by (EC50 at DAT)
-1/ (EC50 at SERT)
-1; higher value = greater DAT selectivity.
(d)  Fully efficacious as an uptake blocker at SERT and indication that it may not act as substrate-type releaser. 
Note: In this follow-up study to Brandt et al., 2014, (S)-(+)-3,4-methylenedioxymethamphetamine ((S)-(+)-MDMA)) was employed as the control, which reflected the fact 
that this substance is a well-characterised, non-selective substrate-type releaser (Baumann et al., 2007), which was consistent with the data reported in Figure 5 and 
Table 4. All three test compounds were shown to be non-selective, with DAT/SERT ratios of 0.6 for MDMA, 1.6 for cis-4,4′-DMAR and 2.5 for trans-4,4′-DMAR (McLaugh-
lin et al., 2014).
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Pharmacokinetics
Published pharmacokinetic data for 4,4′-DMAR in animals or 
humans are not available. A report published on the in vivo 
metabolism of 4-methylaminorex (4-MAR) in Sprague-Dawley 
rats following a single oral and intravenous administration 
(10 mg/kg) revealed the identification of three metabolites in 
urine. In addition to the parent molecule 4-MAR (major 
constituent), the oxazolidinone derivative (oxidative 
deamination), para-hydroxylated 4-MAR and norephedrine 
were detected (Henderson et al., 1995). It is conceivable 
therefore that in the case of 4,4′-DMAR detection of the 
ring-opened, para-methylated norephedrine-type counterpart 
may also be expected. It is worth noting that this latter analyte 
has also been detected as a mephedrone metabolite (Meyer et 
al., 2010). More recent work published on the conversion of all 
stereoisomers of cis- and trans-4-MAR to their norephedrine/
norpseudoephedrine metabolites (adult male Han/Wistar rats; 
intravenous, intraperitoneal, and oral routes of administration 
at 2 mg/kg) confirmed differences in pharmacokinetic 
parameters and tissue distribution. Interestingly, the trans-
(4R,5R)-isomer differed significantly from the remaining 
isomers as it displayed high oral bioavailability and more than a 
3-fold longer elimination half-life (Meririnne et al., 2004). 
Details on the potential for stereospecific pharmacokinetics 
related to 4,4′-DMAR have not been described.
Interactions with other substances
Given the current lack of data, it is difficult to predict with 
accuracy any potential drug interactions or contraindications. 
Briefly, as noted above, the ability of both cis-and trans-4,4′-
DMAR to display potent monoamine transporter activity in vitro 
may be relevant when considering potential interactions with 
other substances that act on similar targets that effect 
dopamine, norepinephrine and serotonin levels. For example, 
the use of substances including medicinal products, known to 
increase 5-HT-release and/or reuptake (such as selective 
serotonin reuptake inhibitors (SSRIs), MDMA and cocaine) may 
increase the risk of developing serotonergic toxicity (often also 
referred to as serotonin syndrome), the symptoms of which can 
include tachycardia, hypertension, hyperthermia, muscle 
rigidity and convulsions (Boyer and Shannon, 2005; Isbister et 
al., 2007; Sternbach, 1991). High dosage levels and/or 
combinations of 4,4′-DMAR with other amphetamine-type 
substances, e.g. catecholamine releasing agents, may lead to 
increasing risk of developing psychotic symptoms and agitation, 
while potentially dangerous cardiovascular effects could be 
produced by excessive norepinephrine release in the periphery. 
The available information related to deaths reported to the EU 
Early Warning System indicated that in 30 of the 31 deaths one 
or more psychoactive substances (predominantly stimulants) 
were present in the analysed biological samples (Section D).
I A3. Psychological and behavioural effects
There are no published studies assessing the psychological 
and/or behavioural effects of 4,4′-DMAR. Self-reported 
experiences of 4,4′-DMAR use from user websites note a 
range of effects that include: euphoria, change in visual 
perception, mental and physical stimulation, empathic effects, 
nausea, agitation and anxiety. 
It is important to note that it is not possible to confirm the 
specific substance(s) used, nor the purity, dose/amount, etc., 
in respect of self-reported cases. Analyses of new 
psychoactive substances or products containing them that 
are sold on the drug market have shown that the composition 
can differ from that claimed by the retailer, and can vary over 
geographical areas and time. Furthermore, the users’ physical 
characteristics and health status are rarely reported. In 
addition, the information on user websites should be regarded 
as illustrative only and not taken as representative of users of 
4,4′-DMAR in general. Consequently, these reports should be 
interpreted with caution.
I A4. Legitimate uses of the product 
4,4′-DMAR and the corresponding enantiomers are expected 
to become available as an analytical reference standard for 
use in scientific research and forensic applications. A range of 
isomers and closely related derivatives/analogues (28) have 
been featured in a number of patent applications filed by the 
pharmaceutical company Hoffmann-La Roche, which describe 
their uses as ligands for the trace amine associated receptor 1 
(TAAR1) related to a range of potential applications to central 
nervous system disorders (Decoret et al., 2010; Galley et al., 
2008). The (4S,5S)-trans-4,4′-DMAR enantiomer has been 
featured in several patents related to the preparation of a 
range of phospholipase A2 inhibitors (e.g. Takagi et al., 2003), 
thus giving rise to the associated CAS number shown in Table 
2. The remaining three forms have not yet been encountered in 
the existing scientific and patent literature. 
There are currently no other indications that 4,4′-DMAR may 
be used for other legitimate purposes. There are no known 
uses of 4,4′-DMAR as a component in industrial, cosmetic or 
agricultural products. There is no information that 4,4′-DMAR 
is currently used in the manufacture of a medicinal product in 
the European Union. However, in the absence of a European 
Union database on the synthetic routes of all medicinal 
products this information cannot be confirmed. There is no 
marketing authorisation (existing, ongoing or suspended) for 
4,4′-DMAR neither in the European Union nor in the Member 
(28)  Example: (4R)-5,5-dimethyl-4-phenyl-4,5-dihydro-1,3-oxazol-2-amine or 
4-ethyl-4-phenyl-4,5-dihydro-1,3-oxazol-2-amine.
RISK ASSESSMENTS I 4,4′-DMAR
23 / 46
Annex 1: Technical report
States that responded to the request for information from the 
European Medicines Agency (EMCDDA and Europol, 2014). 
I  Section B. Dependence and abuse potential
I B1. Animal in vivo and in vitro data 
There are no published animal studies that have examined the 
dependence and abuse potential of 4,4′-DMAR.
I B2. Human data 
There are no published studies investigating the dependence 
and/or abuse potential of 4,4′-DMAR in humans. In addition, 
there are no published case reports describing the potential 
for dependence or abuse potential for 4,4′-DMAR. No 
information is available from drug treatment agencies about 
the dependence and abuse potential. It was not possible to 
ascertain the dependence-producing properties or the abuse 
potential associated with 4,4′-DMAR from user websites.
I Section C. Prevalence of use
I  Information from seizures, collected and biological samples
The first official notification of 4,4′-DMAR to the EU Early 
Warning System was on 10 December 2012 by the 
Netherlands national focal point. The Reporting Form details a 
seizure of 500 g of white powder seized on 19 November 2012 
by customs authorities at Amsterdam. The importation was 
noted to have arrived from India. 
Information provided to Europol
Europol received reports from four Member states with 
regards to level of production, distribution and trafficking. 
Finland reported a small seizure that took place on 23 May 
2013. It was a confiscation of two tablets containing 4,4′-
DMAR (customs authorities in Helsinki), which arrived in a 
parcel coming from the United Kingdom. This seizure was also 
reported by the Finnish national focal point to the EMCDDA on 
2 July 2013. 
Hungary reported that 4,4′-DMAR had been used to make 
tablets, and that this tableting was presumably carried out in 
Hungary, but further details were not available. A total of 78 
seizures were reported by police between June and October 
2013. 4,4′-DMAR was seized as tablets (41 seizures) and in 
powder form (37 seizures). Quantities of tablets seized ranged 
from a single tablet to 900 tablets, with three seizures above 
100 tablets and a total of 1 852 tablets seized. Quantities of 
seized powder ranged from 0.01 g to 193 g, with 27 seizures 
below 1 g and a total weight of 337 g seized. In most cases, 
4,4′-DMAR was reported as the only active substance; in 
about 20 % of detections it was found in combination with 
other substances (predominantly stimulants), including 
pentedrone (eight cases, two of which also contained PVP or 
alpha-PVP) and mephedrone (one case), RH-34 (two cases), 
5-APDB (one case), bk-MPA (one case), ethylphenidate (one 
case), the synthetic cannabinoid receptor agonist UR-144 (one 
case) and the common cutting agent creatine monohydrate 
(one case). In a separate case, 4,4′-DMAR was found in 
combination with four cathinones (methcathinone, MPPP, 
pentedrone and alpha-PVP) (see footnotes in Section A1.1). 
The EMCDDA received the same information from the 
Hungarian national focal point. In the majority of cases 
powdered samples were white, but the presence of pink, 
green and blue powder has also been reported. Tablets have 
been observed to appear in different colours and in specific 
shapes, or bearing specific logos such as ‘Playboy’, ‘Heart’, 
‘Mitsubishi’, ‘Star’ and ‘Transformers’ (EMCDDA and Europol, 
2014). According to Hungarian authorities, the number of 
seizures related to 4,4′-DMAR significantly decreased after the 
introduction of control measures.
As noted above, the Netherlands reported the first detection 
of 4,4′-DMAR in December 2012. It was a shipment of a parcel 
containing 500 g of pale yellow powder. The package was sent 
from India and was destined for a well-known wholesaler of 
new psychoactive substances in the Netherlands. On the 
shipping documents, the substance was declared (and 
misspelled) as: ‘4,5-DYHYDRO-4-METHYL-5(-4-
METHYLPHENYL)-2-OXAZOLAM’.
In Romania, 4,4′-DMAR was identified in 14 seizures. In 13 
cases the substance was seized as a white powder, having a 
total weight of 564.23 g. In the other case five tablets 
containing 4,4′-DMAR were seized. It was also stated that in all 
cases the substance was shipped from abroad and intended 
for so-called ‘own consumption’. No further details were 
provided. The Romanian national focal point also reported 13 
of these seizures to the EMCDDA.
No reports were received that indicated licit or illicit production 
of 4,4′-DMAR in any of the Member States, Turkey and Norway. 
However, the Netherlands reported an incident from 2009 
related to the production of 4-MAR, which is closely related to 
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4,4′-DMAR. The case involved the discovery of an illicit 
production site. The forensic examination of the site, conducted 
by the Netherlands Forensic Institute, demonstrated that both 
MDMA via the bromosafrole route and piperonyl methyl ketone 
PMK (3,4-methylenedioxy phenylpropan-2-one) via the Wacker 
method had been produced. Several different types of 
substances, chemicals and recipes were also found. In addition, 
two white plastic trays were found containing a few hundred 
grams of white powder which was found to contain 4-MAR. 
Moreover, according to the forensic examination, the 4-MAR 
was produced at the site. While not related to 4,4′-DMAR, this 
case would suggest that the capability to manufacture  
4,4′-DMAR may exist within illicit drug-producing criminal 
groups in the European Union.
Information provided to the EMCDDA
The EMCDDA has received reports of detections of 
4,4′-DMAR (29) from nine Member States (Denmark, Finland, 
France, Hungary, the Netherlands, Poland, Romania, Sweden 
and the United Kingdom). 
4,4′-DMAR has typically been seized as powders or tablets. In 
most cases, 4,4′-DMAR was reported as the only active 
substance; in about 20 % of detections it was found in 
combination with other substances (Section A1.2). 
Hungary reported the majority of seizures (78 cases). While 
the remaining Member States reported a small number of 
seizures, it is worth noting that in the case of the Netherlands 
these totalled more than 90 kg of powder (30). Sweden and 
Denmark reported that 4,4′DMAR was detected in seizures of 
pink/red/purple octagonal tablets bearing the markings ‘ST’ 
on one side and ‘60’ on the other. According to user websites, 
the ‘ST’ refers to ‘Serotoni’ and ‘60’ refers to a 60 mg dose.
Denmark reported a seizure by customs of two purple 
octagonal tablets bearing the markings ‘ST/60’ in May 2013.
Finland reported a seizure by customs of two red tablets in 
May 2013, and Hungary reported a total of 78 seizures.
France reported the identification of 4,4′-DMAR in a white 
powder (604 mg), which appears to have been sold as MDMA; 
the investigation is ongoing. 
(29)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, 
blood, etc.) and/or specimens (tissues, hair, etc.).
(30)  This figure was given as ‘260 kilograms’ in the Joint Report (EMCDDA and 
Europol, 2014); however, the Netherlands national focal point informed the 
EMCDDA that the correct total quantity seized was around 90 kg.
As noted, the Netherlands reported the first seizure of 
4,4′-DMAR to the EMCDDA in December 2012. In addition, 
during 2013 customs authorities in the Netherlands detected 
a further 90 kg (30) of 4,4′-DMAR. No further details are 
available regarding these cases.
Romania reported 13 seizures made by police in 2013. These 
comprised one case of five tablets and 12 cases involving 
powder (amounting to a total of 558.84 g).
Sweden reported two seizures made by customs between 
June and December 2013 — a seizure of 10 g of white 
powder, and a seizure of two (red or red/pink) octagonal 
tablets bearing the markings ‘ST’ on one side and ‘60’ on the 
other.
The United Kingdom reported a number of seizures by police 
in Northern Ireland, amounting to 608 tablets. This included 
three cases of 357 tablets that bore a ‘cherries’ logo and one 
case of 91 tablets that bore a ‘cross’ logo (EMCDDA and 
Europol, 2014). In addition, five plastic bags containing white 
powder (a total amount of 1.81 g) were recovered by police in 
Scotland in April 2014 during the investigation of a death 
related to 4,4′-DMAR (Case 29, Table 5). It was reported that 
the deceased had not intended to obtain 4,4′-DMAR, but 
instead they had possibly wished to obtain mephedrone or 
ketamine.
Biological samples
Three Member States (Hungary, Poland and the United 
Kingdom) reported detections of 4,4′-DMAR in biological 
samples from 31 deaths (eight in Hungary; one in Poland; 
22 in the United Kingdom) and one non-fatal intoxication 
(Poland) (Section D1.2.3). Hungary also reported the 
detection of 4,4′-DMAR in biological samples taken in 18 
criminal cases related to the suspected consumption of 
narcotics. 
Collected samples
The United Kingdom reported the detection of 4,4′-DMAR in a 
collected sample. A 5 g sample was purchased for GBP 60 
(EUR 73) from an Internet retailer (31) in March 2014. The 
product was a white powder, labelled ‘5 g’ ‘4,4′-DMAR’ 
(EMCDDA and Europol, 2014). Analysis revealed the presence 
of cis-4,4′-DMAR as the hydrochloride salt. No additional 
constituents were detected (Brandt et al., 2014).
(31)  www.chems-direct.org. It is noteworthy that the price of 4,4′-DMAR has 
dropped on this website since purchase in late March 2014 (e.g. as of 19 April 
2014: EUR 40 for 5 g). At the time of writing (21 August 2014), the website 
was ‘unavailable due to maintenance’.
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Availability from Internet retailers
EMCDDA monitoring in May 2014 of Internet retailers selling 
4,4′-DMAR identified two retailers that were selling the 
substance. The first site marketed 4,4′-DMAR as a ‘research 
chemical’. It was advertised in powder form only, with 
quantities ranging from 500 mg (EUR 18.10) to 100 g 
(EUR 220). All quantities above 500 mg appeared to be 
offered with large price discounts ranging from 55–80 % 
depending on the quantity purchased. This retailer was the 
same site from which the collected sample of 4,4′-DMAR was 
obtained (reported by the United Kingdom). The second site 
offered 4,4′-DMAR in powder form; further details, including 
on the quantities available and price, were only available on 
application to the site. Four retailers were identified who 
appear to have discontinued the sale of 4,4′-DMAR; the 
reasons for the apparent discontinuation of the sale of this 
substance were not provided. An earlier study undertaken in 
April 2014 identified one Internet site selling 4,4′-DMAR with 
similar reduction in price per gram with increasing purchase 
quantities (Nizar et al., 2014). This study identified 20 Internet 
sites selling 4-MAR. Based on this data it would appear that 
the availability of 4,4′-DMAR from Internet retailers is limited.
Prevalence of use
There are currently no coordinated national or European 
surveys on the prevalence of use of 4,4′-DMAR in the general 
population or in targeted populations. Further, neither the 
European School Survey Project on Alcohol and Other Drugs 
(ESPAD) nor other school/college/university surveys have 
investigated or reported on 4,4′-DMAR use. Information from 
seizures and deaths (Section D1.2.3) reported by the Member 
States suggests that in some cases 4,4′-DMAR is sold as 
ecstasy and other illicit drugs, although the extent of this is 
unknown.
Information from poison information services
The National Poisons Information Service in the United 
Kingdom, which provides information on the number of 
accesses to information held on its online poisons information 
database TOXBASE® and details of telephone enquiries made 
to the service by health professionals, reported eight accesses 
to TOXBASE® between 12 February and the end of June 2014, 
which indicates that the need for access to information with 
regards to this particular substance has been limited (32).
(32)  There have been two telephone enquiries involving the use of a product 
termed ‘Euphoria’ and its involvement in adverse reactions (including 
agitation and pyrexia). As noted in Section A1.1, the term ‘Euphoria’ was used 
as a street name for 4-methylaminorex. Further information, for example 
analytical confirmation or whether ‘euphoria’ was a branded product sold as 
a new psychoactive substance, is unavailable. 
I Section D. Health risks
I D1. Acute health effects
D1.1. Animal data
No studies were identified that have investigated the adverse 
events and acute toxicity of 4,4′-DMAR in animal models.
D1.2. Human data
No clinical studies were identified that have examined the 
adverse events and acute toxicity of 4,4′-DMAR in humans. 
D1.2.1. User reports
There are few self-reported user experiences on user 
websites that discuss the subjective effects of 4,4′-DMAR (33), 
including adverse effects. The number of posts that describe 
detailed experiences with the substance is more limited, as 
compared to more established psychostimulants and 
‘research chemicals’. There is a need to interpret these user 
reports with caution since there was no analytical 
confirmation of the substances used (see caveat in Section 
A3). In addition, some of the users describe taking other 
drugs prior to or with 4,4′-DMAR. 
The onset is described as being noticed within 10 to 60 
minutes, although it appears to take longer in some 
individuals, thus possibly leading to re-dosing while waiting 
for the initial effects to be noticed (34). Effects appear to last 
several hours (35,36) and increases in heart rate and body 
temperature have been noted (37). One user who reported 
having taken alcohol and an unspecified ‘triple re-uptake 
inhibitor’ prior to using 4,4′-DMAR noted increased heart 
rate, increased body temperature, jaw clenching, facial 
spasms, sweating, stimulation, psychosis and 
hallucinations (38). 
The French national focal point provided information that 
noted recommendations from users on French language user 
(33)  For example, ukchemicalresearch.org, 2014; drugs-forum.com, 2014; 
chemsrus.com, 2014.
(34)  www.chemsrus.com/forum/14-trip-reports/37810-serotoni-repeated-
dosing-familiar-feel (21 August 2014).
(35)  www.drugs-forum.com/forum/showthread.php?t=216908 (August 2014).
(36)  www.zoklet.net/bbs/showthread.php?t=289735 (August 2014).
(37)  www.bluelight.org/vb/threads/676724-4-4-Dimethylaminorex-(4-5-dihydro-
4-methyl-5-(4-methylphenyl)-2-Oxazolamine) (15 August 2014).
(38)  www.ukchemicalresearch.org/Thread-Serotoni-Powder-Serotonin-
Syndrome-and-Stimulant-Psychosis (August 2014).
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websites to avoid ‘any other products and specifically 
serotoninergic [sic] products at least 4 days before and after 
tacking [sic] product’. It was also noted that users who may 
have developed tolerance to stimulants may require longer 
time periods before noticing the effects (> 1.5 hours). The 
‘comedown’ period has been described to be long lasting, up 
to 12 hours. Undesired after-effects were perceived to be less 
demanding than those experienced with MDMA if appropriate 
dosage regimes were followed.
D1.2.2. 4,4′-DMAR associated acute toxicity
Since October 2013 a total of 32 serious adverse events (39) 
associated with 4,4′-DMAR have been reported to the EU Early 
Warning System. Of the 32 cases, one was a non-fatal 
intoxication and 31 were deaths. The presence of 4,4′-DMAR 
was analytically confirmed in all 32 cases.
Poland reported the preliminary details of a non-fatal 
intoxication, which occurred in September 2013. A 16-year-old 
female was admitted to hospital with suspicion of intoxication 
with ‘legal highs’. Based on information from witnesses, she 
had been smoking an unknown herbal mixture after which she 
felt ill, collapsed and vomited. On admission to hospital the 
patient was in a generally fair condition, with verbal contact, 
dilated pupils, blood pressure of 110/70 and heart rate of 
89 bpm. The next day alarming symptoms were observed (not 
further described). A blood sample (further details were not 
reported) was collected 24 hours after admission and found 
to contain 0.448 mg/L 4,4′-DMAR. The investigation is 
currently ongoing. 
Information provided by Member States related to 4,4′-DMAR 
associated deaths (also involving other substances) note a 
number of adverse effects, including: agitation, hyperthermia, 
convulsions, breathing problems and cardiac arrest (Section 
D1.2.3).
D1.2.3. 4,4′-DMAR associated deaths
A total of 31 deaths associated with 4,4′-DMAR were reported 
by Hungary (eight deaths), Poland (one death) and the United 
Kingdom (22 deaths) (40). The deaths in Hungary occurred 
(39)  Serious adverse event means any adverse event associated with the 
consumption of a new psychoactive substance in a human that: results in 
death; is life-threatening; requires hospitalisation; results in persistent or 
significant disability or incapacity; consists of a congenital anomaly or birth 
defect; or is an important medical event that may not be immediately 
life-threatening or result in death or hospitalisation but may jeopardise the 
patient or may require intervention to prevent one of the other outcomes 
listed above should also be considered serious. Examples of such events are 
intensive treatment in an emergency room; convulsions that do not result in 
hospitalisation; or the development of substance dependency or substance 
abuse. This definition was adapted from the guidelines of ICH (1994).
(40)  Eighteen of the deaths from the United Kingdom have been formally 
published as a case series to alert the scientific community about the 
presence of 4,4′-DMAR on the illicit drug market (Cosbey, et al., 2014).
between June and October 2013, the Polish death in July 
2013 and those in the United Kingdom between June 2013 
and June 2014. The cause of death has not yet been reported 
for most of the cases. Table 5 provides the available details on 
these cases.
Data on gender and age were available for 30 of the 
decedents. Twenty-two were males aged between 18 and 41 
(four from Hungary; the deceased from Poland; 17 from the 
United Kingdom) and eight were females aged between 16 
and 43 years (four from Hungary; four from the United 
Kingdom).
4,4′-DMAR was detected in post-mortem biological samples 
in all 31 deaths. 4,4′-DMAR was quantified in 26 of the 
deaths, with concentrations ranging from less than 
0.02 mg/L to 18.68 mg/L in blood, and from 5.93 mg/L to 
43.49 mg/L in urine. In all apart from one case, other 
stimulants (including cocaine, amphetamines and new 
psychoactive substances such as synthetic cathinones) were 
also found (Table 5). 
In an attempt to evaluate the toxicological significance of 
4,4′-DMAR in the deaths reported, an assessment of the 
following evidence was considered in each case: presence 
and concentration (and pharmacological nature) of 4,4′-DMAR; 
presence and concentration (and pharmacological nature) of 
other drugs present (including alcohol); circumstances of 
death; pathological findings at post-mortem, and cited cause 
of death. This allowed categorisation of the significance of 
4,4′-DMAR in the deaths as being of low significance 
(i.e. alternative cause of death), medium significance 
(i.e. 4,4′-DMAR may have contributed to toxicity/death but 
other drugs present may have been more toxicologically 
significant) or high significance (i.e. 4,4′-DMAR was cited as 
the cause of death or was assessed to have been likely to 
contribute to toxicity/death even in the presence of other 
drugs). In order to highlight potential interactions or 
contributing toxicology, the other substances found in the 
cases were characterised.
The results of this assessment concluded that in 23 deaths 
4,4′-DMAR was either the cause of death (three cases) or is 
likely to have contributed to death (20 cases) even in the 
presence of other substances; in one of these deaths 
4,4′-DMAR was the sole drug present. In eight deaths 
4,4′-DMAR may have contributed to toxicity but other 
substances were present that may have been more 
toxicologically significant. In 27 cases other stimulants 
(including cocaine, amphetamines and new psychoactive 
substances such as synthetic cathinones) were found.
RISK ASSESSMENTS I 4,4′-DMAR
27 / 46
Annex 1: Technical report
TA
B
LE
 5
D
ea
th
s 
as
so
ci
at
ed
 w
it
h 
4
,4
′-D
M
A
R
 r
ep
or
te
d 
to
 t
he
 E
U
 E
ar
ly
 W
ar
ni
ng
 S
ys
te
m
C
as
e
M
S
D
at
e 
of
 
de
at
h
A
ge
S
ex
M
at
ri
x
4
,4
′-D
M
A
R
 
co
nc
en
tr
at
io
n
O
th
er
 s
ub
st
an
ce
s 
de
te
ct
ed
 a
nd
 
co
nc
en
tr
at
io
n 
(w
he
re
 a
va
ila
bl
e)
A
d
ve
rs
e 
ev
en
ts
/a
ut
op
sy
 fi
nd
in
gs
A
dd
it
io
na
l i
nf
or
m
at
io
n 
re
po
rt
ed
1
H
U
Ju
n
e 
2
01
3
25
M
B
lo
od
f
U
rin
e
1
.1
5
8 
m
g
/L
43
.4
9
3 
m
g
/L
7-
A
m
in
o
-c
lo
na
ze
p
am
 0
.1
4
0
5 
m
g
/L
 
al
p
ha
-P
V
P
 0
.0
0
5
6 
m
g
/L
 
P
en
te
d
ro
n
e 
0
.0
27
4 
m
g
/L
7-
A
m
in
o
-c
lo
na
ze
p
am
 0
.0
9
61
 m
g
/L
 
al
p
ha
-P
V
P
 0
.0
9
0
8 
m
g
/L
 
C
lo
na
ze
p
am
 0
.0
13
7 
m
g
/L
 
4
-M
E
C
 6
.5
2
2 
m
g
/L
 
P
en
te
d
ro
n
e 
15
.2
76
 m
g
/L
H
ig
h 
b
od
y 
te
m
p
er
at
ur
e,
 h
ug
e 
b
le
ed
in
g 
in
 th
e 
m
us
cl
es
.
N
o 
in
fo
rm
at
io
n 
on
 ro
u
te
 o
f a
d
m
in
is
tr
at
io
n;
 
h
ow
ev
er
, ‘
th
er
e 
w
as
 n
o 
p
in
-p
ric
k’
.
2
H
U
Ju
n
e 
2
01
3
25
F
B
lo
od
f
0
.0
42
7 
m
g
/L
A
m
p
h
et
am
in
e 
0
.4
91
8 
m
g
/L
 
al
p
ha
-P
V
P
 0
.2
3
5
7 
m
g
/L
 
M
id
az
ol
am
 0
.2
37
4 
m
g
/L
H
ig
h 
b
od
y 
te
m
p
er
at
ur
e,
 h
ug
e 
b
le
ed
in
g 
in
 th
e 
m
us
cl
es
, a
n
d 
or
ga
ns
. 
C
on
fu
si
on
, d
is
or
ie
nt
at
io
n,
 
un
co
ns
ci
ou
sn
es
s,
 p
er
sp
ira
tio
n
.
In
je
ct
ed
, u
se
 a
b
ou
t 3
p
m
, 1
2 
h
ou
rs
 la
te
r d
ie
d 
in
 th
e 
h
os
p
ita
l.
3
H
U
Ju
n
e 
2
01
3
18
M
B
lo
od
u
+ 
(n
o 
q
ua
nt
ita
tio
n)
M
ep
h
ed
ro
n
e 
(n
o 
q
ua
nt
ita
tio
n)
 
M
D
M
A
 (n
o 
q
ua
nt
ita
tio
n)
 
P
en
te
d
ro
n
e 
(n
o 
q
ua
nt
ita
tio
n)
M
yo
cl
on
us
, u
n
co
ns
ci
ou
sn
es
s,
 b
od
y 
te
m
p
er
at
ur
e:
 4
2
.9
°C
, i
nt
er
na
l b
le
ed
in
g 
(o
ra
l, 
in
te
st
in
al
), 
ca
rd
ia
l a
n
d 
re
sp
ira
to
ric
al
 a
rr
es
t. 
A
u
to
p
sy
: l
ar
ge
 
b
ra
in
 o
ed
em
a,
 d
iff
us
e 
in
te
rn
al
 
b
le
ed
in
g,
 b
le
ed
in
g 
in
 lu
ng
s,
 d
ila
ta
tio
n 
of
 th
e 
rig
ht
 v
en
tr
ic
le
 a
n
d 
at
riu
m
. 
W
en
t o
u
t, 
d
id
 n
ot
 g
o 
h
om
e.
 H
is
 p
ar
en
ts
 fo
un
d 
hi
m
 o
n 
th
e 
st
re
et
, i
n 
p
oo
r c
on
d
iti
on
. 
A
m
b
ul
an
ce
 to
ok
 h
im
 to
 th
e 
h
os
p
ita
l, 
h
e 
d
ie
d 
th
e 
n
ex
t m
or
ni
ng
.
4
H
U
A
ug
 2
01
3
43
F
B
lo
od
f
U
rin
e
2
.0
5
5 
m
g
/L
5
.9
2
8 
m
g
/L
M
ep
h
ed
ro
n
e 
0
.5
72
3 
m
g
/L
 
al
p
ha
-P
V
P
 0
.0
14
 m
g
/L
 
A
lp
ra
zo
la
m
 0
.1
1
24
 m
g
/L
M
ep
h
ed
ro
n
e 
0
.3
21
5 
m
g
/L
 
al
p
ha
-P
V
P
 0
.0
0
5
6 
m
g
/L
 
A
lp
ra
zo
la
m
 0
.0
5
3
4 
m
g
/L
 
O
H
-A
lp
ra
zo
la
m
 0
.0
27
 m
g
/L
—
S
h
e 
w
as
 fo
un
d 
at
 h
om
e,
 h
ad
 d
ie
d 
2
–
3 
d
ay
s 
b
ef
or
e.
 N
o 
in
fo
rm
at
io
n 
on
 ro
u
te
 o
f 
ad
m
in
is
tr
at
io
n;
 h
ow
ev
er
, ‘
th
er
e 
w
as
 n
o 
p
in
-p
ric
k’
.
5
H
U
S
ep
t 
2
01
3
2
0
F
B
lo
od
f
U
rin
e
3
.5
6
5 
m
g
/L
3
2
.9
45
 m
g
/L
A
lp
ra
zo
la
m
 0
.0
9
51
 m
g
/L
 
al
p
ha
-P
V
P
 0
.0
2
9
6 
m
g
/L
 
P
en
te
d
ro
n
e 
0
.1
73
0 
m
g
/L
 
T
H
C
-C
O
O
H
 0
.0
1
27
 m
g
/L
P
en
te
d
ro
n
e 
4
4.
5
4
4 
m
g
/L
 
A
m
p
h
et
am
in
e 
0
.3
5
3 
m
g
/L
 
al
p
ha
-P
V
P
 0
.0
8
4
4 
m
g
/L
 
A
lp
ra
zo
la
m
 0
.0
16
7 
m
g
/L
—
S
h
e 
d
ie
d 
af
te
r a
 p
ar
ty
. N
o 
in
fo
rm
at
io
n 
on
 
ro
u
te
 o
f a
d
m
in
is
tr
at
io
n;
 h
ow
ev
er
, ‘
th
er
e 
w
as
 
n
o 
p
in
-p
ric
k’
.
6
H
U
O
ct
 2
01
3
18
F
B
lo
od
u
+ 
(n
o 
q
ua
nt
ita
tio
n)
M
D
A
 0
.0
25
1 
m
g
/L
 
M
D
M
A
 0
.1
9
8
9 
m
g
/L
A
gi
ta
tio
n,
 s
w
ea
t, 
p
al
e.
 4
1
.2
°C
 
te
m
p
er
at
ur
e,
 g
lu
co
se
 1
.7
 m
m
ol
/L
. 
A
u
to
p
sy
: b
ra
in
 o
ed
em
a,
 b
le
ed
in
g 
an
d 
oe
d
em
a 
in
 th
e 
lu
ng
s,
 ‘s
h
oc
k’
 k
id
n
ey
s.
S
h
e 
co
ns
um
ed
 d
ru
gs
 w
ith
 h
er
 fr
ie
n
d 
in
 th
e 
af
te
rn
oo
n
. P
ar
en
ts
 to
ok
 h
er
 to
 th
e 
h
os
p
ita
l, 
af
te
r o
n
e 
h
ou
r s
h
e 
d
ie
d
. (
A
rr
iv
ed
: 2
3
:0
5
, d
ie
d
: 
0
0
:0
4.
) 
RISK ASSESSMENTS I 4,4′-DMAR
28 / 46
Annex 1: Technical report
C
as
e
M
S
D
at
e 
of
 
de
at
h
A
ge
S
ex
M
at
ri
x
4
,4
′-D
M
A
R
 
co
nc
en
tr
at
io
n
O
th
er
 s
ub
st
an
ce
s 
de
te
ct
ed
 a
nd
 
co
nc
en
tr
at
io
n 
(w
he
re
 a
va
ila
bl
e)
A
d
ve
rs
e 
ev
en
ts
/a
ut
op
sy
 fi
nd
in
gs
A
dd
it
io
na
l i
nf
or
m
at
io
n 
re
po
rt
ed
7
H
U
O
ct
 2
01
3
27
M
B
lo
od
u
U
rin
e
+ 
(n
o 
q
ua
nt
ita
tio
n)
+ 
(n
o 
q
ua
nt
ita
tio
n)
M
D
A
 0
.0
4 
m
g
/L
 
M
D
M
A
 0
.8
8
6
3 
m
g
/L
 
M
ep
h
ed
ro
n
e 
0
.0
3
6
3 
m
g
/L
M
D
A
 (n
o 
q
ua
nt
ita
tio
n)
 
M
D
M
A
 (n
o 
q
ua
nt
ita
tio
n)
 
M
ep
h
ed
ro
n
e 
(n
o 
q
ua
nt
ita
tio
n)
M
ild
 b
ra
in
 o
ed
em
a,
 s
h
oc
k,
 in
 th
e 
h
ea
rt
 
rig
ht
 a
tr
ia
l a
n
d 
ve
nt
ric
ul
ar
 d
ila
ta
tio
n,
 
in
te
st
in
al
 b
le
ed
in
g.
H
e 
co
ns
um
ed
 d
ru
gs
 w
ith
 h
is
 fr
ie
n
d
s 
at
 1
8
:3
0
, 
d
ie
d 
th
e 
n
ex
t m
or
ni
ng
.
8
H
U
O
ct
 2
01
3
37
M
B
lo
od
u
+ 
(c
on
ce
nt
ra
tio
n 
to
 b
e 
co
nfi
rm
ed
)
M
D
A
 (c
on
ce
nt
ra
tio
n 
to
 b
e 
co
nfi
rm
ed
) 
M
D
M
A
 (c
on
ce
nt
ra
tio
n 
to
 b
e 
co
nfi
rm
ed
)
A
u
to
p
sy
: c
ar
d
io
m
yo
p
at
hy
, b
ra
in
 
oe
d
em
a,
 p
ul
m
on
ar
y 
oe
d
em
a,
 to
ns
ill
ar
 
h
er
ni
at
io
n,
 e
m
ol
lie
nt
 b
ra
in
 ti
ss
u
e
—
9
P
L
Ju
ly
 2
01
3
3
4
M
B
lo
od
u
0
.6
7
9 
m
g
/L
N
-E
th
yl
b
up
h
ed
ro
n
e 
0
.3
41
 m
g
/L
M
id
az
ol
am
 0
.0
52
 m
g
/L
al
p
ha
-h
yd
ro
xy
m
id
az
ol
am
 0
.0
3
5 
m
g
/L
A
d
m
it
te
d 
to
 h
os
p
ita
l d
ee
p
ly
 
un
co
ns
ci
ou
s,
 b
re
at
hi
ng
 o
n 
hi
s 
ow
n,
 
w
ith
 n
o 
re
ac
tio
n 
to
 s
en
so
ry
 
st
im
ul
at
io
n,
 fi
xe
d 
d
ila
te
d 
p
up
ils
, 
in
cr
ea
se
d 
m
us
cl
e 
to
nu
s,
 m
us
cl
e 
tr
em
or
, s
p
as
m
 o
f t
h
e 
ja
w
 m
us
cl
es
, 
b
ru
is
in
g 
ar
ou
n
d 
lip
s 
an
d 
ea
rs
, b
lo
od
 
p
re
ss
ur
e 
70
/3
0 
an
d 
p
ul
se
 1
4
0
. P
at
ie
nt
 
w
as
 in
tu
b
at
ed
 a
n
d 
ga
st
ric
 la
va
ge
 w
as
 
p
er
fo
rm
ed
. P
at
ie
nt
 d
ie
d 
of
 c
ar
d
ia
c 
ar
re
st
. R
es
us
ci
ta
tio
n 
w
as
 in
eff
ec
tiv
e.
M
al
e 
w
as
 fo
un
d 
un
co
ns
ci
ou
s 
an
d 
w
ith
 
se
iz
ur
es
 in
 h
is
 ro
om
 a
t 3
.0
0 
p
.m
. H
e 
ha
d 
b
ee
n 
se
en
 th
e 
p
re
vi
ou
s 
ev
en
in
g.
 In
 h
is
 ro
om
, 
a 
nu
m
b
er
 o
f e
m
p
ty
 p
ac
ka
ge
s 
w
er
e 
fo
un
d 
w
ith
 th
e 
fo
llo
w
in
g 
la
b
el
s:
 N
E
B
 (
5 
p
ac
ka
ge
s)
, 
3
,4
 D
M
M
C
 (2
 p
ac
ka
ge
s)
, p
en
te
d
ro
n
e 
(6
 
p
ac
ka
ge
s)
, M
D
A
I (
1 
p
ac
ka
ge
), 
5
-A
P
B
 (1
 
p
ac
ka
ge
), 
b
u
fe
d
ro
n
e 
(3
 p
ac
ka
ge
s)
, E
th
-C
at
 (4
 
p
ac
ka
ge
s)
 , 
M
D
E
C
 (1
 p
ac
ka
ge
), 
3
-M
M
C
 (1
 
p
ac
ka
ge
), 
IG
N
IT
E
 (1
0 
p
ac
ka
ge
s)
, 4
-F
M
A
 (1
 
p
ac
ka
ge
), 
M
X
E
 (1
 p
ac
ka
ge
), 
et
hy
lp
h
en
id
at
e 
(2
 
p
ac
ka
ge
s)
, a
lp
ha
-P
V
P
 (1
 p
ac
ka
ge
) a
n
d 
4,
4 
D
M
A
R
 (1
 p
ac
ka
ge
). 
10
U
K
Ju
n 
2
01
3
3
6
M
B
lo
od
f
0
.6
6 
m
g
/L
B
en
zo
yl
ec
og
ni
n
e 
0
.9
7 
m
g
/L
 
C
oc
ai
n
e 
<
0
.0
5 
m
g
/L
 
C
od
ei
n
e 
<
0
.0
2 
m
g
/L
 
Te
tr
a/
le
va
m
is
ol
e 
(u
n
co
nfi
rm
ed
)
—
—
11
U
K
Ju
n 
2
01
3
25
M
B
lo
od
f
0
.9
 m
g
/L
4
-M
E
C
 0
.0
5 
m
g
/L
 
M
D
M
A
 0
.8
2 
m
g
/L
 
M
D
A
 
P
M
M
A
 0
.1
1 
m
g
/L
 
P
M
A
 
T
H
C
-C
O
O
H
—
D
rin
ki
ng
 h
ea
vi
ly
, t
oo
k 
‘m
et
ha
d
ro
n
e’
, 
co
nt
in
u
ed
 d
rin
ki
ng
, t
oo
k 
2 
‘e
cs
ta
sy
’ t
ab
s 
im
m
ed
ia
te
ly
 fe
lt 
un
w
el
l, 
ag
ita
te
d
. 
U
nr
es
p
on
si
ve
 1
 h
ou
r l
at
er
.
1
2
U
K
Ju
n 
2
01
3
3
3
M
B
lo
od
f
0
.2
8 
m
g
/L
B
en
zo
yl
ec
og
ni
n
e 
0
.0
4 
m
g
/L
—
B
el
ie
ve
d 
to
 h
av
e 
ta
ke
n 
‘c
oc
ai
n
e 
an
d 
ec
st
as
y’
. 
D
ec
ea
se
d 
ha
d 
ta
ke
n 
‘s
p
ec
kl
ed
 c
h
er
rie
s 
ta
b
le
ts
’ o
ra
lly
. C
er
eb
ra
l o
ed
em
a 
at
 p
os
t 
m
or
te
m
, s
us
p
ec
te
d 
to
 h
av
e 
ta
ke
n 
d
ru
gs
 a
t 
14
:3
0
, f
ou
n
d 
un
co
ns
ci
ou
s 
th
e 
fo
llo
w
in
g 
d
ay
 
at
 0
7:
3
0
, d
ie
d 
in
 h
os
p
ita
l t
h
e 
d
ay
 a
ft
er
 a
t 
10
:3
0
.
13
U
K
Ju
n 
2
01
3
27
M
B
lo
od
f
0
.7
 m
g
/L
B
en
zo
yl
ec
og
ni
n
e 
0
.3
6 
m
g
/L
 
M
D
M
A
 0
.1
9 
m
g
/L
 
M
D
A
 
M
ir
ta
za
p
in
e 
(a
 lo
w
 le
ve
l) 
In
d
ic
at
io
ns
 o
f l
ow
 le
ve
l o
f c
oc
ai
n
e
—
4,
4
′-D
M
A
R
 d
et
ec
te
d 
w
ith
 c
oc
ai
n
e 
on
 n
as
al
 
sw
ab
s.
 F
ou
n
d 
d
ea
d 
on
 a
rr
iv
al
 o
f a
m
b
ul
an
ce
 
se
rv
ic
e,
 ta
b
le
ts
 a
n
d 
p
ow
d
er
 fo
un
d 
w
h
en
 
h
ou
se
 s
ea
rc
h
ed
.
RISK ASSESSMENTS I 4,4′-DMAR
29 / 46
Annex 1: Technical report
C
as
e
M
S
D
at
e 
of
 
de
at
h
A
ge
S
ex
M
at
ri
x
4
,4
′-D
M
A
R
 
co
nc
en
tr
at
io
n
O
th
er
 s
ub
st
an
ce
s 
de
te
ct
ed
 a
nd
 
co
nc
en
tr
at
io
n 
(w
he
re
 a
va
ila
bl
e)
A
d
ve
rs
e 
ev
en
ts
/a
ut
op
sy
 fi
nd
in
gs
A
dd
it
io
na
l i
nf
or
m
at
io
n 
re
po
rt
ed
14
U
K
Ju
l 2
01
3
2
9
M
B
lo
od
f
<
0
.0
2 
m
g
/L
P
M
A
 0
.0
9 
m
g
/L
 
D
ia
ze
p
am
 p
lu
s 
m
et
ab
ol
ite
 0
.1
4 
m
g
/L
 
T
H
C
-C
O
O
H
 
In
d
ic
at
io
ns
 o
f l
id
oc
ai
n
e
H
e 
ap
p
ea
re
d 
‘w
ip
ed
 o
u
t’,
 w
as
 a
gi
ta
te
d 
an
d 
ov
er
h
ea
tin
g,
 b
eg
an
 fo
am
in
g 
at
 
m
ou
th
.
Fr
ie
n
d 
p
ur
ch
as
ed
 1
0 
x 
sp
ec
kl
ed
 c
h
er
rie
s 
fo
r 
£
5
0
, t
w
o 
w
ee
ks
 p
rio
r f
ro
m
 a
n 
un
kn
ow
n 
m
al
e 
in
 a
 b
ar
. S
oc
ia
lis
in
g 
w
ith
 fr
ie
n
d
s 
at
 h
is
 fl
at
 
d
rin
ki
ng
 a
lc
oh
ol
, t
ak
in
g 
‘E
’ ‘
sp
ec
kl
ed
 c
h
er
ry
’, 
w
itn
es
s 
d
es
cr
ib
es
 h
im
 ta
ki
ng
 3
 x
 ‘s
p
ec
kl
ed
 
ch
er
ry
’ E
 ta
b
s 
ov
er
 th
e 
co
ur
se
 o
f t
h
e 
ev
en
in
g.
15
U
K
Ju
l 2
01
3
4
0
M
B
lo
od
f
1
.2
5 
m
g
/L
M
D
M
A
 0
.0
2 
m
g
/L
 
D
ia
ze
p
am
 0
.0
5 
m
g
/L
 
T
H
C
-C
O
O
H
—
C
on
su
m
ed
 a
lc
oh
ol
, e
cs
ta
sy
 a
n
d 
ca
nn
ab
is
, 
fo
un
d 
d
ea
d 
th
e 
n
ex
t d
ay
, n
ot
hi
ng
 a
t p
os
t 
m
or
te
m
.
16
U
K
A
ug
 2
01
3
41
M
B
lo
od
f
3
.1
3 
m
g
/L
M
D
M
A
 0
.3
 m
g
/L
  
M
D
A
 
C
ita
lo
p
ra
m
 0
.4
2 
m
g
/L
 
E
p
ile
p
tic
 t
yp
e 
se
iz
ur
e 
p
rio
r t
o 
d
ea
th
.
D
ec
ea
se
d 
ha
d 
ta
ke
n 
‘s
p
ec
kl
ed
 c
h
er
rie
s 
ta
b
le
ts
’. 
A
lc
oh
ol
ic
, h
ea
vy
 in
ta
ke
 p
rio
r t
o 
d
ea
th
, 
ep
ile
p
tic
 t
yp
e 
se
iz
ur
e 
p
rio
r t
o 
d
ea
th
, t
ab
le
ts
 
at
 s
ce
n
e.
17
U
K
A
ug
 2
01
3
18
F
B
lo
od
f
2
.1
 m
g
/L
b
k-
M
D
M
A
 0
.8
4 
m
g
/L
  
4
-M
E
C
 0
.7
2 
m
g
/L
 
F
M
C
 
T
H
C
-C
O
O
H
 (
lo
w
 le
ve
l)
—
D
ec
ea
se
d 
ha
d 
ta
ke
n 
‘s
p
ec
kl
ed
 c
h
er
rie
s 
ta
b
le
ts
’. 
D
ie
d 
at
 h
om
e 
fo
llo
w
in
g 
a 
h
ou
se
 
p
ar
ty
 (s
am
e 
lo
ca
tio
n)
 a
ft
er
 c
on
su
m
in
g 
an
 
un
kn
ow
n 
q
ua
nt
it
y 
of
 e
cs
ta
sy
 ta
b
le
ts
 a
n
d 
‘m
et
h
’, t
ab
le
ts
 d
es
cr
ib
ed
 a
s 
gr
ey
 w
ith
 c
h
er
ry
 
lo
go
, w
itn
es
se
s 
sp
ec
ul
at
e 
sh
e 
co
ns
um
ed
 
2
–
3 
ta
b
le
ts
.
18
U
K
A
ug
 2
01
3
19
F
B
lo
od
f
B
lo
od
u  
(a
nt
e 
m
or
te
m
)
~
0
.8
5 
m
g
/L
1
.8
 m
g
/L
4
-M
M
C
 ~
0
.0
45
 m
g
/L
4
-M
M
C
 <
0
.0
1 
m
g
/L
 
4
-M
E
C
 <
0
.0
1 
m
g
/L
 
b
k-
M
D
M
A
 <
0
.0
1 
m
g
/L
—
C
ol
la
p
se
d 
at
 a
 p
ar
ty
, s
us
p
ec
te
d 
ov
er
d
os
e,
 
ta
ke
n 
to
 h
os
p
ita
l u
n
co
ns
ci
ou
s 
an
d 
la
te
r d
ie
d
. 
W
itn
es
se
s 
d
es
cr
ib
ed
 h
er
 ‘c
on
su
m
in
g 
ec
st
as
y 
an
d 
sn
or
tin
g 
“m
et
h
”’.
19
U
K
A
ug
 2
01
3
2
0
M
B
lo
od
f
1
.6
 m
g
/L
4
-M
E
C
 1
.6
8 
m
g
/L
 
b
k-
M
D
M
A
 0
.2
6 
m
g
/L
 
4
-M
M
C
 (
lo
w
 le
ve
l) 
D
ia
ze
p
am
 (
lo
w
 le
ve
l) 
T
H
C
-C
O
O
H
 
In
d
ic
at
io
ns
 F
M
C
S
u
ff
er
ed
 s
ei
zu
re
.
D
ec
ea
se
d 
ha
d 
ta
ke
n 
‘s
p
ec
kl
ed
 c
ro
ss
 ta
b
le
t’.
 
S
u
ff
er
ed
 s
ei
zu
re
 a
n
d 
d
ie
d
, u
ni
d
en
tifi
ed
 
ta
b
le
ts
 a
n
d 
9
.3
6 
g 
of
 p
ow
d
er
 w
as
 s
ei
ze
d 
at
 
th
e 
sc
en
e.
 P
ow
d
er
 c
on
ta
in
ed
 4
-M
E
C
, 
b
k-
M
D
M
A
, f
m
c?
 (n
o 
q
ua
nt
ifi
ca
tio
n)
. U
n
cl
ea
r i
f 
th
is
 p
ow
d
er
 w
as
 li
nk
ed
 to
 th
e 
d
ec
ea
se
d 
as
 
m
or
e 
th
an
 o
n
e 
p
er
so
n 
w
as
 p
re
se
nt
 in
 th
e 
h
ou
se
. 4
,4
′-D
M
A
R
 a
n
d 
4
-M
M
C
 d
et
ec
te
d 
on
 
na
sa
l s
w
ab
s 
ta
ke
n 
p
os
t-
m
or
te
m
.
2
0
U
K
S
ep
 2
01
3
21
M
B
lo
od
f
0
.2
1 
m
g
/L
4
-M
M
C
 0
.0
2 
m
g
/L
 
4
-M
E
C
 0
.1
 m
g
/L
 
b
k-
M
D
M
A
 0
.0
7 
m
g
/L
 
D
ia
ze
p
am
 0
.0
3 
m
g
/L
 
T
H
C
-C
O
O
H
 
A
m
io
d
ar
on
e
A
gi
ta
te
d 
st
at
e,
 s
w
ea
tin
g 
p
ro
fu
se
ly
, 
an
d 
ha
d 
p
ro
b
le
m
s 
b
re
at
hi
ng
.
A
lc
oh
ol
, o
n
e 
or
 t
w
o 
ec
st
as
y 
ta
b
le
ts
, s
p
ec
kl
ed
 
ch
er
ry
 p
os
si
b
ly
 g
re
en
, ‘
m
et
ha
d
ro
n
e’
 h
ad
 
b
ee
n 
co
ns
um
ed
. T
ak
en
 to
 h
os
p
ita
l (
ar
ri
ve
d 
18
:5
7
), 
af
te
r t
ak
en
 il
l a
t a
 h
ou
se
 p
ar
ty
. 
A
gi
ta
te
d 
st
at
e,
 s
w
ea
tin
g 
p
ro
fu
se
ly
, a
n
d 
ha
d 
p
ro
b
le
m
s 
b
re
at
hi
ng
, d
et
er
io
ra
te
d 
ra
p
id
ly
, 
p
ro
n
ou
n
ce
d 
d
ea
d 
2
3
:1
0
. H
ad
 b
ee
n 
p
ar
ty
in
g 
fo
r t
h
e 
p
re
vi
ou
s 
tw
o/
th
re
e 
d
ay
s.
 
RISK ASSESSMENTS I 4,4′-DMAR
30 / 46
Annex 1: Technical report
C
as
e
M
S
D
at
e 
of
 
de
at
h
A
ge
S
ex
M
at
ri
x
4
,4
′-D
M
A
R
 
co
nc
en
tr
at
io
n
O
th
er
 s
ub
st
an
ce
s 
de
te
ct
ed
 a
nd
 
co
nc
en
tr
at
io
n 
(w
he
re
 a
va
ila
bl
e)
A
d
ve
rs
e 
ev
en
ts
/a
ut
op
sy
 fi
nd
in
gs
A
dd
it
io
na
l i
nf
or
m
at
io
n 
re
po
rt
ed
21
U
K
S
ep
 2
01
3
31
M
B
lo
od
f
1
.7
2 
m
g
/L
B
en
zo
yl
ec
og
ni
n
e 
0
.5
5 
m
g
/L
 
In
d
ic
at
io
ns
 o
f l
ow
 le
ve
ls
 o
f c
oc
ai
n
e 
an
d 
d
es
m
et
hy
ld
ia
ze
p
am
C
ar
d
ia
c 
ar
re
st
.
D
rin
ki
ng
 a
n
d 
ta
ki
ng
 d
ru
gs
 (e
cs
ta
sy
 a
n
d 
co
ca
in
e,
 4
 x
 ‘b
lu
e’
) i
n 
hi
s 
h
om
e 
w
ith
 t
w
o 
fr
ie
n
d
s 
in
 th
e 
m
or
ni
ng
, b
ec
am
e 
un
w
el
l a
t 
11
:0
0
, u
nr
es
p
on
si
ve
 w
h
en
 p
ar
am
ed
ic
s 
at
te
n
d
ed
, t
ak
en
 to
 h
os
p
ita
l, 
su
ff
er
ed
 c
ar
d
ia
c 
ar
re
st
, a
n
d 
d
ie
d 
at
 1
2
:2
4.
 T
w
o 
w
itn
es
se
s 
al
so
 
ad
m
it
te
d 
to
 h
os
p
ita
l, 
on
e 
sa
id
 th
ey
 h
ad
 a
ll 
ta
ke
n 
d
ru
gs
 a
n
d 
d
ec
ea
se
d 
ha
d 
ta
ke
n 
4 
‘b
lu
es
’ i
n 
on
e 
go
. 
2
2
U
K
N
ov
 2
01
3
21
M
B
lo
od
f
1
.7
5 
m
g
/L
b
k-
M
D
M
A
 0
.1
4 
m
g
/L
 
4
-M
E
C
 0
.0
6 
m
g
/L
 
4
-M
M
C
 0
.0
4 
m
g
/L
 
T
H
C
-C
O
O
H
18
:0
0
: s
w
ea
tin
g,
 p
ar
an
oi
d 
th
ou
gh
ts
; 
m
id
ni
gh
t: 
sw
ea
tin
g 
p
ro
fu
se
ly
, 
co
nv
ul
si
on
, c
ar
d
ia
c 
ar
re
st
.
N
o 
p
re
vi
ou
s 
hi
st
or
y 
of
 d
ru
g 
ab
us
e.
 Th
ou
gh
t t
o 
ha
ve
 ta
ke
n 
e 
ta
b
s.
 M
ir
ta
za
p
in
e 
p
re
sc
rib
ed
, 
at
ro
p
in
e 
an
d 
ad
re
na
lin
e 
ad
m
in
is
te
re
d
.
2
3
U
K
N
ov
 2
01
3
16
F
B
lo
od
f
1
.1
 m
g
/L
In
d
ic
at
io
ns
 o
f d
ia
ze
p
am
 (
lo
w
 le
ve
l) 
Li
d
oc
ai
n
e 
A
m
io
d
ar
on
e 
M
et
hy
lp
re
d
ni
so
lo
n
e?
C
ar
d
ia
c 
ar
re
st
.
C
ar
d
ia
c 
ar
re
st
 w
hi
le
 o
u
t w
ith
 fr
ie
n
d
s.
 P
M
H
 
as
th
m
a.
24
U
K
D
ec
 2
01
3
3
0
M
B
lo
od
f
<
0
.0
2 
m
g
/L
O
la
n
za
p
in
e 
0
.6
6 
m
g
/L
 
D
ia
ze
p
am
 p
lu
s 
m
et
ab
ol
ite
 0
.4
1 
m
g
/L
 
C
od
ei
n
e 
0
.1
3 
m
g
/L
 
P
ar
ac
et
am
ol
 1
1
.1
 m
g
/L
  
In
d
ic
at
io
ns
 p
re
ga
b
al
in
—
H
is
to
ry
 o
f d
ru
g 
m
is
us
e,
 o
ve
rd
os
es
 a
n
d 
m
en
ta
l i
lln
es
s.
25
U
K
D
ec
 2
01
3
3
3
M
B
lo
od
f
1
.0
1 
m
g
/L
4
-M
E
C
 (
lo
w
 le
ve
l) 
b
k-
M
D
M
A
 0
.2
2 
m
g
/L
 
D
ia
ze
p
am
 p
lu
s 
m
et
ab
ol
ite
 (
lo
w
 le
ve
l) 
T
H
C
-C
O
O
H
—
Th
ou
gh
t t
o 
ha
ve
 ta
ke
n 
‘p
la
nt
 fo
od
’.
2
6
U
K
D
ec
 2
01
3
—
—
B
lo
od
f
1
.7
2 
m
g
/L
T
H
C
-C
O
O
H
 
B
A
C
 5
3 
m
g
%
 
U
A
C
 8
7 
m
g
%
—
Fo
un
d 
d
ea
d 
in
 b
ed
, h
ad
 b
ee
n 
d
rin
ki
ng
 
h
ea
vi
ly
, h
is
to
ry
 o
f d
ru
g 
ab
us
e 
in
cl
u
d
in
g 
ec
st
as
y.
27
U
K
D
ec
 2
01
3
41
M
B
lo
od
f
3
.7
5 
m
g
/L
4
-M
E
C
 0
.5
3 
m
g
/L
 
M
D
M
A
 0
.7
2 
m
g
/L
 
M
D
A
 
T
H
C
-C
O
O
H
 
Q
u
et
ia
p
in
e 
(a
 lo
w
 le
ve
l)
S
ha
ki
ng
 a
ll 
ov
er
, s
w
ea
tin
g,
 h
av
in
g 
a 
fit
, 
ha
n
d
s 
st
u
ck
 o
p
en
 w
ith
 fi
ng
er
s 
sq
u
ee
zi
ng
 to
ge
th
er
 li
ke
 c
la
w
s.
C
al
l t
o 
am
b
ul
an
ce
 s
er
vi
ce
 re
p
or
te
d 
a 
m
al
e 
ta
ki
ng
 e
cs
ta
sy
 a
n
d 
go
in
g 
in
to
 c
ar
d
ia
c 
ar
re
st
. 
A
t t
h
e 
tim
e 
of
 h
is
 d
ea
th
 h
e 
w
as
 h
os
tin
g 
a 
p
ar
ty
, a
 la
rg
e 
q
ua
nt
it
y 
of
 d
ru
gs
 w
er
e 
al
le
ge
d
ly
 
av
ai
la
b
le
, ‘
co
ca
in
e,
 s
p
ec
kl
ed
 R
ol
ex
 e
cs
ta
sy
 
ta
b
le
ts
, m
ag
ic
 a
n
d 
ca
nn
ab
is
’ a
n
d 
al
co
h
ol
. 
S
ev
er
e 
h
ea
rt
 d
is
ea
se
 a
t p
os
t m
or
te
m
.
2
8
U
K
Fe
b 
2
01
4
3
5
M
B
lo
od
f
3
.5
 m
g
/L
b
k-
M
D
M
A
 0
.3
3 
m
g
/L
  
4
-M
E
C
 0
.1
6 
m
g
/L
  
F
M
C
 0
.1
1 
m
g
/L
 
P
ro
cy
cl
id
in
e 
0
.1
1 
m
g
/L
 
D
ia
ze
p
am
 0
.0
6 
m
g
/L
 
D
es
m
et
hy
ld
ia
ze
p
am
 0
.0
9 
m
g
/L
 
T
H
C
-C
O
O
H
Fi
tt
in
g,
 u
n
co
ns
ci
ou
s 
an
d 
b
re
at
hi
ng
.
Ta
ki
ng
 e
cs
ta
sy
 ta
b
le
ts
 a
n
d 
le
ga
l h
ig
hs
, ‘
ta
ki
ng
 
co
ca
in
e 
an
d 
ec
st
as
y’
, ‘
fit
tin
g,
 u
n
co
ns
ci
ou
s 
an
d 
b
re
at
hi
ng
’ w
h
en
 a
m
b
ul
an
ce
 c
al
le
d 
at
 
ap
p
ro
x.
 0
3
:1
3
, p
ol
ic
e 
an
d 
am
b
ul
an
ce
 a
rr
iv
ed
 
0
3
:2
1
, d
ec
ea
se
d
. O
th
er
 p
er
so
n 
p
re
se
nt
 ta
ke
n 
to
 h
os
p
ita
l d
es
cr
ib
ed
 a
s 
cr
iti
ca
l.
RISK ASSESSMENTS I 4,4′-DMAR
31 / 46
Annex 1: Technical report
C
as
e
M
S
D
at
e 
of
 
de
at
h
A
ge
S
ex
M
at
ri
x
4
,4
′-D
M
A
R
 
co
nc
en
tr
at
io
n
O
th
er
 s
ub
st
an
ce
s 
de
te
ct
ed
 a
nd
 
co
nc
en
tr
at
io
n 
(w
he
re
 a
va
ila
bl
e)
A
d
ve
rs
e 
ev
en
ts
/a
ut
op
sy
 fi
nd
in
gs
A
dd
it
io
na
l i
nf
or
m
at
io
n 
re
po
rt
ed
2
9
U
K
A
p
ril
 2
01
4
19
F
B
lo
od
~1
m
g
/L
 
(c
is
-is
om
er
 
co
nfi
rm
ed
) (
n
o 
ce
rt
ifi
ed
 
re
fe
re
n
ce
 
m
at
er
ia
l s
o 
n
ot
 
re
p
or
te
d 
q
ua
nt
ita
tiv
el
y)
N
on
e 
d
et
ec
te
d
B
ec
am
e 
ag
ita
te
d 
an
d 
co
lla
p
se
d
, h
ig
h 
te
m
p
er
at
ur
e 
(3
8
.9
oC
)
D
ec
ea
se
d 
b
el
ie
ve
d 
sh
e 
ha
d 
ta
ke
n 
‘M
C
AT
’ 
(m
ep
h
ed
ro
n
e)
. C
P
R
 p
er
fo
rm
ed
 b
y 
fr
ie
n
d
s 
at
 
th
e 
sc
en
e 
un
til
 p
ar
am
ed
ic
s 
to
ok
 o
ve
r. 
W
itn
es
se
s 
un
co
op
er
at
iv
e 
w
ith
 p
ol
ic
e 
re
ga
rd
in
g 
d
ru
g 
us
e.
ci
s-
4,
4
′-D
M
A
R
 w
as
 s
ta
te
d 
as
 th
e 
ca
us
e 
of
 
d
ea
th
.
3
0
U
K
Ju
n
e 
2
01
4
2
9
M
B
lo
od
f
1
.6
8 
m
g
/L
M
D
M
A
 0
.6
9 
m
g
/L
 E
th
yl
p
h
en
id
at
e 
(l
ow
 
co
n
c.
), 
co
ca
in
e 
(l
ow
 c
on
c.
)
S
ig
ni
fic
an
t b
od
y 
st
iff
n
es
s 
w
as
 
ob
se
rv
ed
.
C
ol
la
p
se
d 
in
 g
ar
d
en
 a
n
d 
b
el
ie
ve
d 
to
 h
av
e 
ta
ke
n 
‘M
ia
ow
’ (
n
ot
e:
 n
am
e 
of
te
n 
as
so
ci
at
ed
 w
ith
 m
ep
h
ed
ro
n
e)
.
C
au
se
 o
f d
ea
th
 w
as
 re
p
or
te
d 
as
 M
D
M
A
 a
n
d 
4,
4
′-D
M
A
R
 to
xi
ci
ty
.
31
U
K
Ju
n
e 
2
01
4
27
M
B
lo
od
f
18
.6
8 
m
g
/L
M
ep
h
ed
ro
n
e 
15
.7
3 
m
g
/L
 
C
oc
ai
n
e 
0
.4
6 
m
g
/L
B
en
zo
yl
ec
og
ni
n
e 
> 
2
m
g
/L
 L
ev
am
is
ol
e 
(l
ow
 c
on
c.
) 
H
yd
ro
xy
zi
n
e 
(l
ow
 c
on
c.
)
R
ep
or
te
d 
to
 b
e 
tw
itc
hy
 a
n
d 
sw
ea
tin
g.
 
S
ig
ni
fic
an
t b
od
y 
rig
id
it
y 
w
as
 o
b
se
rv
ed
.
C
ol
la
p
se
d 
an
d 
b
el
ie
ve
d 
to
 h
av
e 
ta
ke
n 
co
ca
in
e.
C
au
se
 o
f d
ea
th
 re
p
or
te
d 
as
 c
oc
ai
n
e,
 
m
ep
h
ed
ro
n
e 
an
d 
4,
4
′-D
M
A
R
 to
xi
ci
ty
.
K
ey
: 
M
S
: M
em
b
er
 S
ta
te
; H
U
: H
un
ga
ry
; P
L:
 P
ol
an
d;
 U
K
: U
ni
te
d 
K
in
gd
om
; M
: m
al
e;
 F
: f
em
al
e;
 B
lo
od
f : 
fe
m
or
al
 b
lo
od
 s
am
p
le
; B
lo
od
u :
 s
it
e 
of
 b
lo
od
 s
am
p
le
 u
ns
p
ec
ifi
ed
; –
: n
ot
 re
p
or
te
d
.
RISK ASSESSMENTS I 4,4′-DMAR
32 / 46
Annex 1: Technical report
I D2. Chronic health effects
D2.1. Animal data
There are no published studies investigating the chronic 
health effects of 4,4′-DMAR in animals.
D2.2. Human data
There are no published studies investigating the chronic 
health effects of 4,4′-DMAR in humans.
I D3. Factors affecting public health risks
D3.1. Availability and quality of the new psychoactive 
substance on the market 
4,4′-DMAR is sold as a drug in its own right and offered for sale 
by Internet retailers and in both retail and wholesale 
quantities. It has been sold as a ‘research chemical’ and in 
octagonal tablets with the markings ‘ST’ and ‘60’ called 
‘Serotoni’. In comparison to many other more commonly 
advertised new psychoactive substances or ‘research 
chemicals’, it also appears that the number of Internet retailers 
that offer this particular substance is limited (Section C).
Information from seizures and deaths associated with 
4,4′-DMAR reported by Member States indicates that 
4,4′-DMAR has also been sold as ecstasy and other illicit 
drugs. Seized street tablets found to contain 4,4′-DMAR 
showed a range of markings and logos (41), raising the 
likelihood that these particular products were designed to be 
sold as ‘ecstasy’ tablets on the illicit drug market.
D3.2. Availability of information, degree of knowledge 
and perceptions amongst users concerning the 
psychoactive substance and its effects
Relative to other more commonly advertised new 
psychoactive substances or ‘research chemicals’, there 
appears to be limited information on popular user websites 
regarding the effects and potential health/adverse effects 
related to the use of 4,4′-DMAR (Section D1.2.1). At the time of 
writing (42), no entry in the ‘Erowid Experience Vaults’ (43) 
(41)  It is common to find markings on tablets sold as ‘ecstasy’ including those of 
popular cultural and iconic brands often having an association with quality.
(42)  15 August 2014. 
(43)  Users have the opportunity to submit their experiences and ‘trip reports’ to this 
drug information website: www.erowid.org/experiences/exp_front.shtml.
could be identified. The users and forum discussion 
participants appear to be generally aware of the stimulant-
type (wanted and unwanted) effects of this substance.
D3.3. Characteristics and behaviour of users 
No studies were identified that have examined the 
characteristics and behaviour of users of 4,4′-DMAR. There are 
self-reported user experiences where individuals have posted 
their experiences with the drug on user websites. In cases 
where 4,4′-DMAR is sold surreptitiously as part of ‘ecstasy’-
type tablet formulations or other illicit drugs, it appears likely 
that these may be taken within environments that may extend 
beyond home use, such as clubbing situations, etc. 
Information from the United Kingdom relating to deaths 
associated with 4,4′-DMAR indicated a pattern of use to be 
‘house party type environment, in combination with other 
drugs, such as cocaine, “ecstasy” type drugs, substituted 
cathinones, diazepam and cannabis’.
D3.4. Nature and extent of health consequence 
The limited information on the acute health effects of 
4,4′-DMAR was discussed in Section D1.2. There is insufficient 
information in the reported deaths where 4,4′-DMAR has been 
detected to discuss in detail the circumstances of these cases 
and the potential impact on road traffic accidents or 
psychological functioning. 
D3.5. Long-term consequences of use
As noted in Sections D2.1 and D2.2, there are no animal or 
human data on the chronic health effects of 4,4′-DMAR use.
D3.6. Conditions under which the new psychoactive 
substance is obtained and used, including context-
related effects and risks
As noted, it appears that the sourcing and use of 4,4′-DMAR 
can be related to either individuals attempting to source the 
drug itself from online sources, for example as a ‘research 
chemical’. In other cases it has been sold/provided 
surreptitiously as ecstasy or other illicit drugs. It is likely that 
4,4′-DMAR is used in the same environments as other 
stimulant-type drugs. This would be typically (but not 
restricted to) home environments (Section D3.3), 
discotheques/nightclubs and outdoor music festivals.
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I Section E. Social Risks
I E1. Individual social risks
No data are available to determine the impact of 4,4′-DMAR in 
this area.
I E2. Possible effects on direct social environment
No data are available to determine the impact of 4,4′-DMAR in 
this area.
I E3. Possible effects on society as a whole
No data are available to determine the impact of 4,4′-DMAR in 
this area. 
I E4. Economic costs
No data are available to determine the impact of 4,4′-DMAR in 
this area.
I  E5. Possible effects related to the cultural context, for example marginalisation
No data are available to determine the impact of 4,4′-DMAR in 
this area.
I  E6. Possible appeal of the new psychoactive substance to specific population groups within the general population
No data are available to determine the possible appeal of 
4,4′-DMAR to specific population groups within the general 
population. 
I Section F. Involvement of organised crime
I  F1. Evidence that criminal groups are systematically involved in production, trafficking and distribution for financial gain
Limited information is available from the Member States in 
relation to the involvement of organised crime in the 
manufacture or trafficking of 4,4′-DMAR. 
According to the Hungarian authorities, organised crime 
groups are involved in the trafficking and distribution of 
4,4′-DMAR; no other details were provided.
The information about the small-scale production of the 
related substance 4-MAR in the Netherlands in 2009 would 
suggest that the capability to manufacture 4,4′-DMAR may 
exist within illicit drug-producing criminal groups in the 
European Union.
I  F2. Impact on the production, trafficking and distribution of other substances, including existing psychoactive substances as well as new psychoactive substances
Based on the information available it does not appear that the 
production, trafficking and distribution of 4,4′-DMAR impacts 
on other existing psychoactive substances or new 
psychoactive substances.
I  F3. Evidence of the same groups of people being involved in different types of crime
No information has been received by Europol of evidence of 
the same groups of people being involved in different types of 
crime in connection with 4,4′-DMAR.
I  F4. Impact of violence from criminal groups on society as a whole or on social groups or local communities (public order and safety)
No information has been received by Europol on incidents of 
violence in connection with 4,4′-DMAR.
I  F5. Evidence of money laundering practices, or impact of organised crime on other socioeconomic factors in society
No information has been received by Europol on incidents of 
money laundering or the impact of organised crime on other 
socioeconomic factors in society in connection with 4,4′-
DMAR.
I  F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial system) 
No data are available to determine the impact of 4,4′-DMAR in 
this area.
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I F7. Use of violence between or within criminal groups
No information has been received by Europol on incidents of 
violence in connection with 4,4′-DMAR.
I  F8. Evidence of strategies to prevent prosecution, for example through corruption or intimidation
No information has been received by Europol on strategies to 
prevent prosecution in connection with 4,4′-DMAR.
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I Council Decision
COUNCIL IMPLEMENTING DECISION (EU) 2015/1873 of 8 October 2015 on subjecting 
4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR) and 1-cyclohexyl-
4-(1,2-diphenylethyl)piperazine (MT-45) to control measures
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk-assessment and control of new psychoactive substances (1), and in 
particular Article 8(3) thereof,
Having regard to the proposal of the European Commission,
Having regard to the opinion of the European Parliament,
Whereas:
(1) A Risk Assessment Report on the new psychoactive substance 4-methyl-5-(4-
methylphenyl)-4,5-dihydrooxazol-2- amine (4,4′-DMAR) was drawn up in accordance with 
Article 6 of Decision 2005/387/JHA by a special session of the extended Scientific 
Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
and was subsequently submitted to the Commission and to the Council on 19 September 
2014.
(2) 4,4′-DMAR is a synthetic substituted oxazoline derivative. It is a derivative of aminorex 
and 4-methylaminorex (4-MAR), two synthetic stimulants controlled under the 1971 United 
Nations Convention on Psychotropic Substances.
(3) 4,4′-DMAR has been available on the drugs market in the Union since at least 
December 2012 and was notified to the Early Warning System in December 2012. Nine 
Member States have reported detections as a result of seizures of the substance, mainly in 
the form of white or coloured powders and tablets, as well as biological and collected 
samples.
(4) 4,4′-DMAR emerged on the new psychoactive substances market as a ‘research 
chemical’ sold by internet retailers, and it is now available on the street market. 4,4′-DMAR 
is being sold and consumed as a substance on its own, but it has also been mis-sold on 
the illicit market as ecstasy and amphetamines.
(5) There have been 31 deaths associated with 4,4′-DMAR registered in three Member 
States, between June 2013 and June 2014. In most cases, 4,4′-DMAR was either the 
cause of death or, together with other substances, is likely to have contributed to death. 
One Member State has reported a case of non-fatal intoxication.
(6) There are no studies on the toxicity of 4,4′-DMAR.
(7) There is no prevalence data on the use of 4,4′-DMAR. However, the information 
available suggests that it has not been widely used. Information obtained from cases 
(1) OJ L 127, 20.5.2005, p. 32.
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involving death also suggests that users unknowingly consumed 4,4′-DMAR when seeking 
other stimulants.
(8) There is limited involvement of organised crime in the manufacture, distribution, 
trafficking and supply of 4,4′-DMAR within the Union. The chemical precursors and the 
synthetic routes used to manufacture 4,4′-DMAR are unknown.
(9) 4,4′-DMAR is not listed for control under the 1961 United Nations Single Convention on 
Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances. 
It is not currently under assessment, and has not been under assessment, by the United 
Nations’ system, and no such assessment is planned.
(10) 4,4′-DMAR has no established or acknowledged human or veterinary medical use in 
the Union. Apart from its use in analytical reference materials, and in scientific research 
investigating its chemistry, pharmacology and toxicology, there is no indication that it is 
being used for other purposes.
(11) The Risk Assessment Report reveals that there is limited scientific evidence available 
on 4,4′-DMAR and points out that further research would be needed to determine the 
health and social risks that it poses. However, the evidence and information currently 
available provides sufficient ground for subjecting 4,4′-DMAR to control measures across 
the Union. As a result of the risks to health that the consumption of 4,4′-DMAR poses, as 
documented by its detection in several fatalities, of the fact that users may unknowingly 
consume it, and of the lack of medical value of this substance, 4,4′-DMAR should be 
subjected to control measures.
(12) Given that three Member States control 4,4′-DMAR under national legislation 
complying with the obligations of the 1971 United Nations Convention on Psychotropic 
Substances and five Member States use other legislative measures to control it, subjecting 
this substance to control measures across the Union would help avoid the emergence of 
obstacles in cross-border law enforcement and judicial cooperation, and would protect 
against the risks that its availability and use can pose.
(13) A Risk Assessment Report on the new psychoactive substance 1-cyclohexyl-4-(1,2-
diphenylethyl)piperazine (MT-45) was drawn up in accordance with Article 6(2), (3) and (4) 
of Decision 2005/387/JHA by a special session of the extended Scientific Committee of 
the EMCDDA, and was subsequently submitted to the Commission and to the Council on 
6 October 2014.
(14) MT-45 is an N,N′-disubstituted piperazine, having a cyclohexane ring attached to one 
of the nitrogen atoms of the piperazine ring and a 1,2-diphenylethyl moiety attached to the 
other nitrogen atom. MT-45 is one of a series of 1-(1,2-diphenylethyl)piperazine analgesics 
invented in the early 1970s.
(15) MT-45 has been present on the drugs market in the Union since October 2013, where 
it is sold as a ‘research chemical’, mostly on the internet. The EMCDDA has identified 12 
sites of internet suppliers and retailers that have offered MT-45 for sale, including some 
apparently based in the Union.
(16) A total of 28 fatalities occurring between November 2013 and July 2014 have been 
reported by one Member State. In most cases, the presence of MT-45 in biological 
samples was analytically confirmed. Some 18 non-fatal intoxications have also been 
reported by the same Member State, the clinical features of which were similar to opioid 
intoxication, responding in some cases to the opioid receptor antagonist naloxone.
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(17) There are several studies in animals indicating that the acute toxicity of MT-45 is 
several-fold higher than that of morphine.
(18) Currently available information suggests that MT-45 has not been widely used. The 
substance appears to be mostly used in the home environment either by users willing to 
try a new substance or by opioid dependent users with no access to heroin or any other 
opioid. Users may combine MT-45 with other psychoactive substances. There is no 
information on the social risks that may be related to MT-45.
(19) There is no evidence of involvement of organised crime in the manufacture, 
distribution, trafficking and supply of MT-45 in the Union. The chemical precursors and the 
synthetic routes used to manufacture the MT-45 detected in Member States are unknown.
(20) MT-45 is not listed for control under the 1961 United Nations Single Convention on 
Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances. 
It is not currently under assessment, and has not been under assessment, by the United 
Nations’ system, and no such assessment is planned.
(21) MT-45 has no established or acknowledged human or veterinary medical use in the 
Union. Apart from its use in analytical reference materials, and in scientific research 
investigating its chemistry, pharmacology and toxicology, there is no indication that it is 
being used for other purposes.
(22) The Risk Assessment Report reveals that there is limited scientific evidence available 
on MT-45 and points out that further research would be needed to determine the health 
and social risks that it poses. However, the evidence and information currently available 
provides sufficient grounds for subjecting MT-45 to control measures across the Union. As 
a result of the health risks that it poses, as documented by its detection in several 
fatalities, and of the lack of medical value of this substance, MT-45 should be subjected to 
control measures.
(23) Given that one Member State controls MT-45 under national legislation complying 
with the obligations under the 1961 United Nations Single Convention on Narcotic Drugs 
and under the 1971 United Nations Convention on Psychotropic Substances and seven 
Member States use other legislative measures to control it, subjecting this substance to 
control measures across the Union would help avoid the emergence of obstacles in 
cross-border law enforcement and judicial cooperation, and would protect against the risks 
that its availability and use can pose.
(24) Decision 2005/387/JHA confers upon the Council implementing powers with a view 
to giving a quick and expertise-based response at Union level to the emergence of new 
psychoactive substances detected and reported by the Member States, by subjecting 
those substances to control measures across the Union. As the conditions and procedure 
for triggering the exercise of such implementing powers have been met, an implementing 
decision should be adopted in order to put 4,4′-DMAR and MT-45 under control across the 
Union.
(25) Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision which implements Decision 2005/387/JHA.
(26) Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision which implements Decision 2005/387/JHA.
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(27) The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not 
taking part in the adoption of this Decision which implements Decision 2005/387/JHA and 
is not bound by it or subject to its application,
HAS ADOPTED THIS DECISION:
Article 1
The following new psychoactive substances shall be subjected to control measures across 
the Union:
(a) 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR);
(b) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45).
Article 2
By 21 October 2016, Member States shall take the necessary measures, in accordance 
with their national law, to subject the new psychoactive substances referred to in Article 1 
to control measures and criminal penalties, as provided for under their legislation 
complying with their obligations under the 1961 United Nations Single Convention on 
Narcotic Drugs and/or under the 1971 United Nations Convention on Psychotropic 
Substances.
Article 3
This Decision shall enter into force on the day following that of its publication in the Official 
Journal of the European Union.
This Decision shall apply in accordance with the Treaties.
Done at Luxembourg, 8 October 2015.
For the Council 
The President 
J. ASSELBORN
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Abbreviations
(R) Levorotatory (rectus)
(S) Dextrorotatory (sinister)
3,4-DMMC 3,4-Dimethylmethcathinone
3-MMC 3-Methylmethcathinone 
4,4’-DMAR 4,4′-dimethylaminorex
4-FMA 4-Fluoromethamphetamine
4-M-4-MAR 4,4′-Dimethylaminorex
4-MAR 4-Methylaminorex
4-MEC 4-Methylethcathinone
4-MMC 4-Methylmethcathinone
5-APB 5-(2-aminopropyl)benzofuran
5-APDB 5-(2-aminopropyl)-2,3-dihydrobenzofuran
5-HT Serotonin
API Active pharmaceutical ingredient
BAC Blood alcohol content
bk-MDMA bk-Methylenedioxymethamphetamine 
(Methylone)
bk-MPA bk-Methylthienylpropamine
Bloodf Femoral blood
Bloodu Unspecified site of blood sample
BrCN Cyanogen bromide
CAS Chemical Abstracts Service registry number
CPR Cardiopulmonary resuscitation
DA Dopamine
DAT Dopamine transporter 
Decision Council Decision 2005/387/JHA of 10 May 2005 
on the information exchange, risk assessment and 
control of new psychoactive substances
EC50 Half maximal effective concentration
ECHA European Chemicals Agency
EI/CI Electron- and chemical ionisation
EI-MS Electron ionisation–mass spectroscopy
ELISA Enzyme linked immunosorbent assay
EMA European Medicines Agency 
ESI Electrospray ionisation
ESI-MS/MS Electrospray ionisation tandem mass 
spectroscopy
ESPAD European School Survey Project on Alcohol and 
other Drugs
Eth-Cat Ethcathinone
EtOH Ethanol
EU European Union
EUR Euro
EWS Early Warning System (EMCDDA–Europol)
FMC Fluoromethcathinone
Abbreviations
FTIR Fourier transform infrared spectroscopy
GBP British Pound
GC Gas chromatography 
GC-MS Gas chromatography–mass spectrometry
HCl Hydrochloric acid
HPLC High performance liquid chromatography 
IUPAC International Union of Pure and Applied Chemistry
KOCN Potassium cyanate
LC Liquid chromatography
LC-MS Liquid chromatography–mass spectrometry
LC-MS/MS Liquid chromatography–tandem mass 
spectrometry 
LD50 Median lethal dose
MCAT 4-Methylmethcathinone (Mephedrone)
MDA 3,4-Methylenedioxyamphetamine
MDAI Methylenedioxyaminoindane
MDEC 3,4-Methylenedioxyethcathinone (Ethylone)
MDMA 3,4-Methylenedioxymethamphetamine
MPP 1-Methyl-4-phenylpyridinium 
MPPP 4’-Methyl-alpha-pyrrolidinopropiophenone
MS Mass spectrometry
MS Member State
MXE Methoxetamine
NaBH4 Sodium borohydride
NE Norepinephrine
NEB N-Ethylbuphedrone
NET Norepinephrine transporter
NMR Nuclear magnetic resonance spectroscopy
p4-DMAR 4,4′-Dimethylaminorex
PMA para-Methoxyamphetamine
PMK Piperonyl methyl ketone
PMMA para-Methoxymethamphetamine
REACH Regulation on registration, evaluation, 
authorisation and restriction of chemicals, 
database hosted by European Chemicals Agency
RH-34 3-[2-(2-Methoxybenzylamino)ethyl]-1H-
quinazoline-2,4-dione
SD Standard deviation
SERT Serotonin transporter
SSRIs Selective serotonin reuptake inhibitors
ST 4,4′-Dimethylaminorex
ST60 4,4′-Dimethylaminorex
TAAR Trace amine associated receptor
THC-COOH Tetrahydrocannabinol-carboxylic acid
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Abbreviations
TOXBASE Clinical toxicology database of the National 
Poisons Information Service (United Kingdom)
UAC Urine alcohol content
UN United Nations
UR-144 (1-Pentyl-1H-indol-3-yl)-(2, 2, 3, 3-tetramethyl-
cyclopropyl)methanone
WHO World Health Organization
α-PVP α-Pyrrolidinovalerophenone
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Participants of the risk assessment meeting, 16 September 2014
Scientific Committee members
I  Dr Henri Bergeron, Centre National de la Recherche Scientifique (CNRS), Institut d’Études Politiques 
de Paris (IEP), Paris
I  Dr Anne-Line Bretteville Jensen, Norwegian Institute for Alcohol and Drug Research, Oslo, Vice-
Chair of the Scientific Committee
I  Prof. Dr Gerhard Bühringer, Addiction Research Unit, Dep. of Clinical Psychology and Psychotherapy, 
Technische Universität Dresden, Institut für Therapieforschung (IFT), Munich, Chair of the Scientific 
Committee
I  Dr Paul Dargan, Clinical Toxicology, St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation 
Trust, London
I  Prof. Dr Matthew Hickman, Social Medicine, Bristol
I  Prof. Dr Dirk J. Korf, Universiteit of Amsterdam, Law Faculty, Amsterdam
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